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CHAPTER I: INTRODUCTION 
 
 
Overview of lung cancer 
 
 
Risk and survival 
 
In the next several years, cancer is expected to surpass heart disease as the 
leading cause of death in the United States. Lung cancer has been the foremost cause 
of cancer-related deaths since the late 1950s for males and since the late 1980s for 
females. In 2015, it was responsible for more than a quarter of all deaths from cancer 
(1). The greatest risk factor for lung cancer, as well as the most preventable, is cigarette 
smoking (2). While reduction in smoking prevalence has reduced lung cancer incidence 
rates in recent years (3), cigarette smoking still accounts for 87% of lung cancer deaths 
(2). Lesser contributors to lung cancer incidence include exposure to radon gas, 
secondhand smoke, asbestos, arsenic, chromium, and nickel. Genetic factors also 
influence lung cancer susceptibility (4). Despite strong advances in lung cancer 
screening and treatment strategies, those diagnosed with lung cancer are usually 
diagnosed with late-stage disease and face a five-year survival rate of only 17% (3).   
 
Histological subclasses 
 
Lung cancer is divided into two major subclasses, small cell lung cancer (SCLC) 
and non-small cell lung cancer (NSCLC). About 10-15% of lung cancers are SCLCs. 
SCLC is characterized by tumor cells of small size, a round-to-spindle shape, very little 
cytoplasm, finely granular nuclear chromatin, and absent or inconspicuous nucleoli. The 
cells are usually arranged in sheets (Figure 1A) (5). NSCLC comprises 85-90% of lung 
cancers and is further divided into three subgroups, adenocarcinoma, squamous cell 
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carcinoma, and large cell carcinoma, based on the cells from which it arises. About 40% 
of NSCLCs are adenocarcinomas, which arise from the peripheral bronchi (6). Tumor 
cells of adenocarcinomas are typically arranged in clusters with sharply defined borders. 
The cells have abundant cytoplasm and round to oval nuclei with prominent nucleoli 
(Figure 1B) (5). Squamous cell carcinomas make up 25-30% of all NSCLCs and arise 
from the main bronchi (7). Tumor cells grow in aggregates within flat sheets and may be 
spindle- and tadpole-shaped with spindle nuclei. Keritanized cytoplasm is detectable in 
well-differentiated tumors (Figure 1C) (5). Large cell carcinomas, often also termed 
NSCLC “not otherwise specified”, make up about 10% of NSCLCs. These tumors lack 
the cytologic features of other lung cancer types, are usually proximal, and rapidly 
spread locally to the mediastinum (Figure 1D) (5, 7).  
 
 
Figure 1: Histopathology of lung cancer subtypes 
Tumor biopsy sections stained with H&E. (A) SCLC; (B) Adenocarcinoma; (C) Squamous cell 
carcinoma; (D) Large cell carcinoma.  
(A) and (D) modified and used with permission from Noguchi M, Shimosato Y. (8). Copyright © 
2010 Lippincott Williams & Wilkins, a Wolters Kluwer business. 
(B) and (C) modified from Travis et al. (9). Originally published by the American Society of Clinical 
Oncology. Travis WD, Brambilla E, Riely GJ: 8(3), 2013: 992-1001. Used with permission. 
A B 
C D 
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Molecular classification of NSCLC 
 
Significant progress in understanding the molecular biology of NSCLC has been 
made in recent years. Research has identified a number of driver mutations that confer 
growth advantages to cancer cells and positively select these cells for survival in the 
lung tumor microenvironment (10). Because these mutations drive oncogenesis, they 
are prime candidates for pharmacological targeting and have been used to molecularly 
classify NSCLC. As depicted in Figure 2, the most common genetic aberrations in 
NSCLC adenocarcinomas are activating mutations in Kirsten rat sarcoma viral oncogene 
homolog (KRAS) and epidermal growth factor receptor (EGFR), which together comprise 
40-50% of all NSCLCs. Genetic rearrangement of anaplastic lymphoma kinase (ALK) 
occurs in 7% of NSCLCs and results in the oncogenic fusion protein echinoderm 
microtubule-associated protein-like 4 (EML4)-ALK. Other less common mutations 
include mesenchymal epithelial transition factor (MET), human epidermal growth factor 
receptor 2 (HER2)/mitogen-activated protein kinase kinase (MEK), B-Raf proto-
oncogene (BRAF), ROS Proto-Oncogene 1 (ROS), and ret proto-oncogene (RET) (11). 
Remarkably, these genetic aberrations tend to be mutually exclusive (12). Driver 
mutations for squamous cell carcinoma include phosphatidylinositol-4,5-bisphosphate 3-
kinase, catalytic subunit alpha (PIK3CA), fibroblast growth factor receptor 1 (FGFR1), 
MET, discoidin domain receptor tyrosine kinase 2 (DDR2), and BRAF. While therapies 
have been developed to target some of these mutations, 40% of adenocarcinomas and 
33% of squamous cell carcinomas still do not have known driver mutations (11).   
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Figure 2: Driver mutations of NSCLC adenocarcinomas 
Pie chart showing percentages of NSCLC adenocarcinomas that have specific driver mutations. 
Modified from Boolel et al. (11). Used with permission under the terms and conditions of the 
Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/). 
 
Figure 3: Driver mutations of NSCLC squamous cell carcinoma 
Pie chart showing percentages of NSCLC squamous cell carcinomas that have specific           
driver mutations. Modified from Boolel et al. (11). Used with permission under the terms and 
conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/4.0/). 
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Treatment of NSCLC 
 
Treatment of lung cancer is based on tumor histology, grade, and molecular 
characteristics. Resectable, early-stage NSCLC is usually treated with surgery, which 
may be followed by chemotherapy with or without radiation (3). Following surgical 
resection, the five-year survival rate for stage I and II NSCLC patients is 60-80% and 30-
50%, respectively (13). While surgery is the best option for prolonging survival in early-
stage NSCLC patients (14), the majority of NSCLC patients (over 70%) are diagnosed 
with non-resectable, advanced-stage disease (9). Treatment for these patients include 
chemotherapy, targeted therapy, or a combination of the two (3).  
With the identification of genetic aberrations in NSCLC, several small molecule 
inhibitors have been developed to target driver mutations. Gefitinib, erlotinib, and afatinib 
are tyrosine kinase inhibitors (TKIs) that have been approved by the Federal Drug 
Administration (FDA) for first-line treatment of advanced or metastatic NSCLC with 
EGFR mutations (15). Gefitinib and erlotinib are first generation reversible TKIs 
specifically targeted to the tyrosine kinase domain of EGFR to prevent anti-apoptotic and 
proliferative signaling (16). They are effective in patients whose tumors have a deletion 
in exon 19 or an L858R point mutation in exon 21 of EGFR (17–21). However, patients 
treated with gefitinib or erlotinib develop resistance to therapy within 8-16 months of 
treatment (22). About half of these patients become resistant through the acquisition of 
an additional T790M mutation in the tyrosine kinase domain of EGFR (22–24). Afatinib 
and osimertinib are second generation TKIs that irreversibly bind EGFR and inhibit 
aberrant signaling resulting from both exon 19 deletions and L858R mutations as well as 
T790M mutations. Gefitinib- and erlotinib-resistant tumors are sensitive to both afatinib 
and osimertinib (25–29); however, tumors still develop resistance within months (25, 26, 
29).  
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TKIs crizotinib, ceritinib, and alectinib have been approved by the FDA for 
treatment of locally advanced or metastatic NSCLCs with ALK gene rearrangements 
(15). Crizotinib, which inhibits ALK, ROS1, and some MET tyrosine kinases, is more 
effective both as first-line and subsequent therapy than chemotherapy in patients with 
ALK-mutant NSCLC (30, 31). However, resistance occurs after about 10 months (32, 
33). Ceritinib and alectinib are approved for treatment of crizotinib-resistant NSCLCs 
with ALK rearrangements. Ceritinib inhibits ALK and insulin-like growth factor 1 (IGF-1), 
while alectinib inhibits ALK and RET (15). Both drugs have a response rate of about 
50% with disease progression occurring 7-12 months after treatment (34, 35). 
Since the majority of NSCLCs diagnosed do not harbor EGFR mutations or ALK 
gene rearrangements, therapies have been developed to inhibit broader targets, 
including angiogenesis and immune checkpoint proteins (16). Angiogenesis is the 
formation of new blood vessels, a process that is crucial for sustained tumor growth (36). 
Bevacizumab is a monoclonal antibody that inhibits angiogenesis by binding to vascular 
endothelial growth factor A (VEGFA). It has been shown to delay disease progression in 
combination with chemotherapy and is approved for treatment of advanced non-
squamous NSCLC (16, 37–39). The TKI nintedanib inhibits several angiogenesis 
pathways and, in combination with chemotherapy, has shown particular benefit in 
patients with adenocarcinoma (16, 40). Nintedanib is approved for treatment of 
advanced adenocarcinoma after failure of first-line chemotherapy in Europe but has not 
yet received approval in the United States (16). Unfortunately, benefits from 
angiogenesis inhibitors, like cancer cell-targeted therapies, last only months before rapid 
resistance develops (41).  
Immune checkpoints are inhibitory pathways within immune cells that are crucial 
for maintaining self-tolerance and preventing inappropriate immune responses that could 
be detrimental to the host (16, 42). In lung and other cancers, tumor cells use immune 
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checkpoints, such as the programmed cell death protein 1 (PD-1) pathway, to render 
immune cells tolerant of tumor antigens, thereby evading attack. Tumor cells 
overexpress programmed cell death ligands 1 and 2 (PD-L1 and 2), which bind to PD-1 
protein on activated T-cells and deactivate them (Figure 4) (16). To prevent this 
mechanism of immune evasion, immune checkpoint inhibitors, including PD-1 inhibitors, 
have been utilized to promote T cell immunity against cancer cells (43–45). 
Pembrolizumab is a PD-1 inhibitor approved for treatment of both non-squamous and 
squamous NSCLC and is especially effective for tumors with high expression of 
programmed cell death ligand 1 (PD-L1) (46). Nivolumab is another FDA-approved PD-1 
inhibitor that improves response duration compared to docetaxel in both non-squamous 
and squamous NSCLCs (47, 48). Recently, a clinical trial investigating nivolumab 
monotherapy vs chemotherapy in patients with previously untreated advanced NSCLC 
whose tumors expressed PD-L1 ≥5% (CheckMate-026, NCT02041533) did not meet its 
primary endpoint of progression-free survival (49). While the patient population was 
broad, these negative results suggest that checkpoint inhibitors may not be quite as 
effective as initially believed. 
 
 
Figure 4: Activation of T cells by anti-PD-1 checkpoint inhibitors 
Left: PD-L1 expressed on a tumor cells binds to PD-1 protein on the surface of a T cell and 
inactivates the T cell; Right: An anti-PD-1 inhibitor binds to PD-1 protein on the surface of a T cell 
and maintains T cell activation. Modified from Minguet et al. (16). Copyright © 1999-2016 John 
Wiley & Sons, Inc. All Rights Reserved. Used with permission. 
 
 
8 
 
Need for alternative treatment options  
 
While great strides have been made in NSCLC treatment within the past decade, 
numerous challenges remain and stress the need for continued development of novel 
therapeutic strategies. Ultimately, to improve lung cancer survival rates, disease will 
need to be detected at earlier stages (50). Lung cancer screening for high-risk 
individuals is imperative to identify candidates for early detection when treatment is likely 
to be most beneficial. In 2011, the National Lung Screening Trial research team 
determined that low-dose computed tomography (CT) detected more early-stage 
NSCLC than radiography and reduced lung cancer mortality (51). Additionally, known 
and novel driver mutations will need to be effectively targeted. For example, KRAS 
mutations are present in 15-20% of NSCLC adenocarcinomas, but despite great efforts, 
no therapy has been established that effectively target mutant KRAS (52).  
A large obstacle in NSCLC treatment is the inevitable development of resistance 
in patients with initial responses. Targeted therapies for EGFR mutations and ALK 
rearrangements clearly demonstrate the ability of initially sensitive tumors to adapt and 
exploit various mechanisms to render treatment ineffective. The challenge of treating 
these patients is to quickly identify and target resistance mechanisms with new drugs to 
keep the cancer in remission (50). Discovering these resistance mechanisms to 
treatment is complex and has its own collection of challenges. Lung tumors are a 
heterogeneous mixture of cancer cells that do not all share the same mutations or 
respond equally to the same drug. A targeted therapy may eliminate only a 
subpopulation of the tumor while the remaining cells continue to grow. Additionally, not 
all tumors employ the same resistance mechanism to specific treatments (50). For 
example, only 50% of NSCLC tumors with exon 19 deletions or L858R mutations in exon 
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21 develop targetable T790M mutations (22–24). Patients with other resistance 
mechanisms have fewer options for subsequent treatment.  
The introduction of angiogenesis and checkpoint inhibitors provided NSCLC 
treatment strategies for patients whose tumors had unknown driver mutations or were 
resistant to EGFR or ALK inhibitors (16). While these treatments may be beneficial in 
patients for a time, eventual disease progression is considered inevitable (41, 53). In 
order to sustain NSCLC remission, a battery of therapies will be required that use 
different mechanisms to overcome resistance and curb disease progression.  
Cancer-related inflammation is one of the hallmarks of cancer and represents 
target for cancer therapeutics that has not been appreciated until recently. It is 
characterized by infiltration of the tumor microenvironment by immune cells, increased 
expression of cytokines and chemokines, tissue remodeling, and angiogenesis (54). 
Most previous efforts have focused on eliminating tumor cells themselves. However, 
targeting inflammatory signaling pathways that are critical for maintaining cancer-related 
inflammation may prove beneficial in single-agent or combination therapy strategies for 
treating lung and other cancers.  
 
Nuclear factor kappa B 
 
Classical and alternative signaling pathways 
 
Nuclear factor kappa B (NF-κB) is a transcription factor family that regulates 
expression of over 450 genes involved in numerous cellular processes (55). The five 
members of the NF-κB family (p65 [RelA], RelB, c-Rel, p105/p50 [NF-κB1], and p100/52 
[NF-κB2]) associate with each other to form homodimers or heterodimers that have 
distinct DNA-binding specificities to κB sites as well as different activation mechanisms 
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(56). In unstimulated cells, NF-κB dimers are bound to inhibitory proteins and 
sequestered in the cytoplasm. The NF-κB pathway is activated by a variety of stimuli, 
including pro-inflammatory cytokines, T- and B-cell mitogens, bacteria, 
lipopolysaccharide (LPS), viruses, viral proteins, double-stranded RNA, and physical and 
chemical stresses (57). Upon pathway activation, the inhibitory proteins are 
phosphorylated and undergo proteasomal degradation, allowing the NF-κB dimers to 
translocate into the nucleus and control gene transcription (58).  
Two distinct NF-κB signaling pathways have been described: the classical 
(canonical) pathway and the alternative (noncanonical) pathway (Figure 5). In the 
classical pathway, the inhibitor of κB (IκB) becomes phosphorylated by IκB kinase 
subunit β (IKKβ), resulting in ubiquitination and proteasomal degradation of IκB. The 
p50/RelA NF-κB heterodimer then translocates to the nucleus and regulates gene 
transcription. p50/RelA is the prototypical NF-κB heterodimer and is expressed in nearly 
all cell types. Its activation induces production of mediators involved in immunity, 
inflammation, proliferation, and apoptosis (58). In the alternative pathway, IKKα 
phosphorylates the IκB-like C-terminal domain of p100, resulting in proteasomal 
processing of p100 to p52. The p52/RelB heterodimer then translocates into the nucleus 
and transcribes downstream target genes (58). While classical NF-κB signaling has 
been studied extensively, much less is known about the functions of the alternative 
pathway. However, the alternative NF-κB pathway has been described to play roles in 
secondary lymphoid organogenesis and architecture organization, thymic epithelial cell 
differentiation, B-cell maturation and survival, dendritic cell maturation, and bone 
metabolism (59).  
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Figure 5: Classical and alternative NF-κB signaling pathways 
Left: In the classical pathway, IKKβ phosphorylates IκB, targeting IκB for ubiquitination and 
subsequent proteasomal degradation. The RelA/p50 heterodimers then translocate to the nucleus 
and regulated gene transcription. Right: In the alternative pathway, IKKα phosphorylates p100, 
leading to proteasomal processing of p100 to p52. The p52/RelB heterodimer then translocates to 
the nucleus and transcribes target genes. Modified and used with permission from Martinka et al. 
(56). Copyright © 2006 the American Physiological Society. 
 
 
 
  
Classical 
(Canonical) 
Alternative 
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Link between NF-κB and cancer 
 
Most solid and lymphoid tumors have activated NF-κB signaling, though the 
causes of increased signaling appear to be different. In several B cell malignancies, 
upstream signaling mediators are mutated or stabilized, resulting in constitutive NF-κB 
signaling (59–66). However, most solid tumors have enhanced NF-κB activation that is 
not associated with genetic alterations in NF-κB, IKK, or upstream components within 
the signaling system. NF-κB activation in lung cancer is significantly associated with 
increased tumor staging and poor prognosis, but direct mutations in NF-κB pathway 
proteins have not been observed (67–69). Instead, constitutive NF-κB activation in lung 
cancer is mediated by activating mutations in oncogenes (EGFR, HER2, BRAF, KRAS, 
etc.) that crosstalk with NF-κB or inactivating mutations in tumor suppressor genes (P53, 
RB, PTEN, STK11) that increase NF-κB transcriptional activity (70–74). NF-κB can also 
be activated by cigarette smoke carcinogens and cigarette smoke-induced chronic lung 
inflammation (75, 76). 
Aberrant NF-κB signaling is recognized as a critical link between inflammation 
and cancer (77). Several different inflammation-associated cancer models have 
demonstrated that NF-κB signaling in epithelial cells contributes to tumorigenesis by 
regulating expression of tumor-associated cytokines and anti-apoptotic genes. In models 
of colitis-associated cancer (78), gastric cancer (79), hepatocellular carcinoma (80), and 
melanoma (81), inhibition of NF-κB signaling in epithelial cells reduced tumor 
number/incidence and resulted in increased apoptosis of transformed epithelial cells. 
Our group has shown that long-term conditional activation of NF-κB signaling via IKKβ 
expression in airway epithelial cells results in increased lung inflammation, leading to an 
immunosuppressive lung microenvironment and formation of lung tumors, even in the 
absence of an additional oncogenic stimulus (82). In agreement, studies using 
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carcinogen, mutant-Kras, and mutant-EGFR lung tumor models have demonstrated that 
NF-κB signaling in airway epithelial cells is crucial for tumorigenesis. Conditional 
activation of NF-κB signaling in airway epithelial cells resulted in increased lung 
inflammation and numbers of lung tumors induced by the complete lung carcinogen 
urethane. Activation of NF-κB signaling was also associated with increased proliferation 
and decreased apoptosis of epithelial cells (83). Conversely, expression of a dominant 
inhibitor of NF-κB in lung epithelial cells of both mice treated with urethane and mice with 
conditional expression of mutant EGFR in lung epithelial cells decreased lung 
inflammation and tumor formation (84, 85). In urethane-treated mice with NF-κB 
inhibition, decreased lung inflammation and tumor formation was associated with 
increased epithelial cell apoptosis (84). In mice with oncogenic EGFR expression, NF-κB 
inhibition reduced recruitment of pro-tumorigenic macrophages to the lung (85). A variety 
of methods (blocking IκB degradation, knockdown of IKKβ, or p65/RelA deletion) have 
been used to knock down epithelial NF-κB signaling in mutant-Kras lung cancer models. 
Each of them found reduced lung tumors as well as increased apoptosis or decreased 
proliferation of epithelial cells (86–88). Collectively, these studies strongly support 
targeting the NF-κB signaling pathway for lung cancer treatment. 
 
Targeting the NF-κB pathway in lung cancer 
 
Over 780 agents have been identified that inhibit NF-κB signaling directly or 
indirectly (89). These include antioxidants as well as inhibitors of upstream targets of 
NF-κB, IKK and IκB phosphorylation, IκB degradation, proteasomes and proteases, NF-
κB nuclear translocation, NF-κB expression, NF-κB DNA binding, and NF-κB 
transactivation (89). The proteasome inhibitor bortezomib is the most well-studied 
inhibitor of NF-κB signaling. Bortezomib blocks signaling through the NF-κB pathway by 
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preventing proteosomal degradation of IκB. It received FDA approval in 2003 for the 
treatment of multiple myeloma (90) and has been involved in over 750 clinical trials as a 
therapeutic for numerous cancer types (ClinicalTrials.gov). While bortezomib increased 
sensitivity of human lung cancer cell lines to chemotherapy-induced apoptosis (91–93), 
bortezomib has not shown efficacy in NSCLC treatment. Bortezomib monotherapy in 
advanced NSCLC patients had limited activity in randomized phase I and II trials (94). 
When combined with chemotherapy or targeted therapy, bortezomib was well-tolerated 
but did not significantly affect tumor responses (95–102). Thus, a future role for 
bortezomib in lung cancer treatment is uncertain. 
Several methods have been employed to investigate the effects of NF-κB 
inhibitor therapy in cell and animal models of lung cancer, showing variable results. 
Directly blocking NF-κB using siRNA, IKK inhibitors, and IκB super suppressors reduced 
cell survival and inhibited proliferation in lung cancer cell lines treated with 
chemotherapy or activators of TNF/TRAIL death receptor pathways (103–105). Similarly, 
indirect NF-κB inhibition using the flavonoids genistein and luteolin sensitized lung 
cancer cell lines to apoptosis induced by chemotherapy and gamma radiation, 
respectively (106, 107). In Kras-mutant mouse studies, Basseres et al. and Xue et al. 
showed short-term lung tumor responses to different NF-κB inhibitor therapies, including 
a specific IKKβ inhibitor (Cmpd A), bortezomib, and BAY 11-7082, an inhibitor of IκBα 
phosphorylation (108, 109). However, long-term responses with these agents were not 
observed. The IKKβ inhibitor was administered for only 4 weeks, and tumors developed 
resistance to bortezomib and BAY 11-7082 within 13 and 8 weeks of treatment, 
respectively (108, 109). Even more, our group has shown that lung tumor formation was 
enhanced, not hindered, in urethane-treated mice administered prolonged treatment with 
bortezomib (110). The mechanism of resistance to bortezomib and other NF-κB inhibitor 
therapies is not known. Though tumor cells could develop intrinsic resistance to NF-κB 
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inhibitors via the acquisition of additional mutations (109), this would likely translate into 
sporadic appearance of secondary resistance, as opposed to the uniform primary 
resistance to bortezomib observed in various solid tumors (101, 102). Alternatively, it is 
possible that separate cell types respond differently to NF-κB inhibition during 
tumorigenesis. 
 
Myeloid Cells 
 
Roles in innate immunity 
 
The lungs are highly populated with innate immune cells known as myeloid cells 
that respond quickly to inhaled particulates and airborne pathogens (111). Myeloid cells 
are bone-marrow derived leukocytes, including neutrophils, macrophages, and dendritic 
cells, and employ a variety of mechanisms to maintain homeostasis in the lungs (Figure 
6). Neutrophils are granulocytic cells that eliminate pathogens primarily by phagocytosis. 
Additionally, they may undergo respiratory burst, releasing granzymes and toxic reactive 
oxygen/nitrogen species. Macrophages and dendritic cells are phagocytic antigen-
presenting cells, which activate T and B cells to initiate adaptive immune responses 
against specific antigens. Both macrophages and dendritic cells release inflammatory 
mediators and cytokines to regulate inflammation and immune responses. Like 
neutrophils, they are also capable of releasing toxic reactive oxygen species to defend 
against pathogens (112).   
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Figure 6: Functions of myeloid cells during innate immune responses. 
Neutrophils, macrophages, and dendritic cells are innate myeloid cells that are first-responders to 
pathogens and other non-host antigens. Each cell type uses a variety of functions to eliminate 
foreign substances and recruit other innate and adaptive immune cells to mount a robust immune 
response. Figure modified and used with permission from Kuby Immunology (112). Table 3-12 in 
Kuby, IMMUNOLOGY, Sixth Edition © 2007 W.H. Freeman and Company. 
 
 
 
Myeloid cells in cancer 
 
Myeloid cells are characterized by remarkable plasticity, altering their phenotypes 
based upon signals received from the surrounding microenvironment. In the context of a 
tumor, myeloid cells have the ability to directly eliminate cancer cells and initiate anti-
tumorigenic immune responses. However, these anti-tumorigenic responses are often 
thwarted by tumor cells themselves, which produce factors that polarize myeloid cells or 
prevent their differentiation so that myeloid cells support tumor growth and progression 
(113). Macrophages, neutrophils, dendritic cells, and myeloid-derived suppressor cells 
(MDSC) are all commonly found in the tumor microenvironment, polarized toward a 
tumor-favoring phenotype (114). Recently, macrophages and neutrophils have been 
heavily studied for their roles during tumorigenesis.  
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In 2002, Mantovani et al. introduced a simplistic paradigm for classically-
activated M1 and alternatively-activated M2 macrophage polarization states based on 
expression of cell surface markers and cytokines (115) (Figure 7). Th1 cytokines and/or 
microbial components (LPS) induce macrophage polarization towards the M1 
phenotype. M1 macrophages mount classic Th1 immune responses, supporting 
resistance to microbes and tumor cells. They produce high levels of IL-12, IL-23, ROS, 
RNS, and inflammatory cytokines (e.g. IL-1β, TNF, and IL-6) (113). In contrast, Th2 
cytokines, such as IL-4 and IL-13, inhibit classical macrophage activation and instead 
induce alternative activation of macrophages. Alternatively-activated M2 macrophages 
highly express the immunosuppressive cytokine IL-10, tumor growth factors (e.g. EGF, 
FGF1, TGFβ1), pro-angiogenic factors (VEGF), matrix remodeling factors (e.g. fibrin and 
MMPs), and chemokines involved in recruitment of Th2 cells and immunosuppressive 
regulatory T cells (Tregs) (CCL17, CCL22, CCL24) (113). They play roles in resolution of 
inflammation, wound healing, angiogenesis, and tissue remodeling (113). Macrophages 
present in or surrounding a tumor are called tumor-associated macrophages (TAM). 
Several experimental studies indicate that TAM have an M2-like phenotype and promote 
tumor formation and progression through angiogenesis, immunosuppression, and 
perpetuation of cancer-associated inflammation (115–118).  
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Figure 7: Polarization of macrophages to anti-tumorigenic M1 or pro-tumorigenic M2 
phenotypes.  
Monocytes are differentiated into two broad phenotypes based on signals they receive from the 
microenvironment. Left: Stimuli that induce the tumor-promoting M2 phenotype include M-CSF, 
IL-4, IL-13, IL-10, corticosteroids, PGE, and vitamin D3. M2 macrophages highly express 
immunosuppressive cytokines, Th2 chemokines, and matrix remodeling factors that promote 
tumors through scavenging, matrix remodeling, tissue repair, and angiogenesis. Right: The M1 
phenotype is induced by GM-CSF, LPS, IFNγ, and bacterial products. Anti-tumorigenic M1 
macrophages secrete Th1 pro-inflammatory cytokines and chemokines as well as reactive 
oxygen and nitrogen intermediates (ROI and RNI, respectively) to elicit bactericidal activity, 
heightened immune responses, and tumor suppression. Reprinted from European Journal of 
Cancer, Volume 42, Issue 6, Sica A, Schioppa T, Mantovani A, Allavena P. Tumour-
associated macrophages are a distinct M2 polarised population promoting tumour progression: 
potential targets of anti-cancer therapy. 717-727, Copyright(2016), with permission from 
Elsevier(119). 
 
 
The role of TAMs during lung tumorigenesis in NSCLC patients is controversial 
but seems to be dependent on both localization and phenotype. Several studies have 
observed a survival benefit in NSCLC patients whose tumors had a high density of 
macrophages (120–122). Further investigation discovered that 70% of macrophages 
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present in lung tumors were of the M1 phenotype, and M1 macrophage density in 
tumors independently predicted increased survival in NSCLC patients (123, 124). In 
contrast, increased macrophage density in the tumor stroma was associated with 
reduced survival (122). One study found that in advanced NSCLC, more than 95% of 
TAMs were located in the tumor stroma and identified as M2-like macrophages. M2 
macrophages were higher in patients with progressive disease (125). This finding was 
confirmed in other studies showing that increasing M2 macrophage density correlated 
with poor prognosis in NSCLC patients (126, 127).  
In addition to macrophages, an N1/N2 paradigm has been proposed by 
Fridlender et al. for neutrophils, with N1 and N2 neutrophils having anti- and pro-
tumorigenic properties, respectively (Figure 8). The N1 phenotype is induced by IFNβ 
(128, 129). N1 neutrophils have hypersegmented nuclei and express high levels of 
immune-activating cytokines and chemokines, adhesion molecule ICAM1, and death 
receptor Fas (130). N1 neutrophils directly kill tumor cells using ROS-mediated tumor 
cell lysis (130–132) or by inducing Fas ligand-associated apoptosis (133). Through 
chemokine and cytokine secretion, N1 neutrophils also recruit and activate CD8+ and 
CD4+ T cells to kill tumor cells and mediate anti-tumoral memory, respectively (130, 
134–137). Expression of TGFβ by tumors induces recruitment of neutrophils to the tumor 
via expression of neutrophil chemoattractant chemokines (CXCL2, CXCL5, and CCL3) 
and polarizes tumor-associated neutrophils (TAN) towards the N2 phenotype (130). N2 
TANs have circular nuclei, expressing high levels of arginase, CCL2, and CCL5 (130) 
and generating low amounts of neutrophil granules and ROS (138). Arginase produced 
by N2 neutrophils inactivates T cells and facilitates pro-tumorigenic immunosuppression 
(139, 140). The chemokines CCL2 and CCL5 produced by N2 TANs also promote 
tumorigenesis by supporting cancer cell proliferation, angiogenesis, and 
immunosuppression (141–143).  
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Figure 8: Polarization of neutrophils to anti-tumorigenic N1 or pro-tumorigenic N2 
phenotypes. 
Neutrophils are polarized toward anti-tumorigenic N1 neutrophils by IFNβ and toward pro-
tumorigenic N2 neutrophils by TGFβ. N1 neutrophils are cytotoxic to tumors and express high 
levels of TNFα, ICAM1, and FAS. They also activate T cells to stimulate a robust anti-tumor 
immune response. N2 neutrophils express high levels of arginase, CCL2, and CCL5, which 
promote tumor growth, support angiogenesis, and/or mediate immunosuppression. 
Figure modified from Thanee et al. (144), which modified from Fridlender et al. (138). Fridlender 
ZG, Albelda SM. Tumor-associated neutrophils: friend or foe?. Carcinogenesis. 2012;33(5):949–
955 by permission of Oxford University Press. 
 
 
The role of TANs during lung tumorigenesis is complex and, like TAMs, appears 
to depend on localization and phenotype. Elevated circulating neutrophil counts have 
been associated with a worse prognosis in advanced NSCLC patients (145–148). 
Neutrophils at the tumor site tend to have an N2 phenotype as a result of TGFβ 
expression by the tumor (149). CD66b+ N2-like TANs are elevated in 50% of resectable 
NSCLC tumors and have been associated with high incidence of relapse and worse 
overall survival (150). On the other hand, another group described an immunostimulating 
N1-like role for TANs in early-stage lung cancer rather than an immunosuppressive role 
(151). Thus, much remains to be elucidated concerning the roles of TANs in NSCLC 
patients.  
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Myeloid-derived suppressor cells (MDSCs) are a heterogeneous mixture of 
immature monocytic and granulocytic myeloid cells that are increased in NSCLC and are 
associated with angiogenesis (152, 153), tumor progression (154), metastatic spread 
(155), and poorer outcomes (156). In mice, MDSCs are identified by positive expression 
of the cell surface markers CD11b and Gr1; in humans, MDSCs are identified using 
positive expression of CD11b and CD33 along with low or absent expression of HLA DR 
(157–160). MDSCs exert their pro-tumorigenic effects by inhibiting the function of 
effector and antigen presenting cells in the tumor microenvironment (160–162). MDSCs 
express PD-L1, which binds to PD-1 on the surface of T effector cells and inactivates 
them (163). Arginase-1 produced by MDSCs induces cell cycle arrest of T effector cells 
(164–166) and inhibits proliferation and secretion of IFNγ by natural killer cells (167). 
Expression of iNOS and ROS by MDSCs results in the generation of reactive nitrogen 
species, such as NO (164, 165). NO has been shown to suppress T cell function via the  
JAK/STAT signaling pathway (168), reducing MHC expression (169), disrupting the TCR 
(170, 171), and inducing T cell apoptosis (172). Finally, expression of IL-10 by MDSCs 
induces polarization of T cells to the immunosuppressive Treg phenotype (173, 174) and 
macrophages to the immunosuppressive M2 phenotype (175). 
 
Inhibition of NF-κB in myeloid cells during tumorigenesis 
 
Several studies have investigated the impact of NF-κB inhibition in myeloid cells 
on tumorigenesis, yielding controversial findings. Blocking myeloid cell-specific NF-κB 
signaling reduced colon tumors and tumor-promoting cytokines in the azoxymethane 
dextran sulfate sodium salt model of colitis-associated carcinoma (78). Similarly, 
Takahashi et al. showed that inhibition of myeloid NF-κB signaling reduced lung tumors 
in Kras-mutant mice in response to tobacco smoke exposure. In this model, myeloid NF-
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κB inhibition also reduced lung inflammation, cytokine expression, and proliferation 
(176). The mechanism responsible for these anti-tumorigenic responses may be through 
induction of classic innate immune responses in TAMs. Blocking NF-κB signaling in 
TAMs has been shown to induce an anti-tumorigenic M1 phenotype that is able to 
promote tumor regression through induction of tumoricidal activity and recruitment of 
natural killer cells (177, 178). In contrast to these beneficial responses to myeloid-
specific NF-κB inhibition, blocking the signaling in cutaneous and lung melanoma 
models rapidly induced tumor growth. Myeloid cells with inhibited NF-κB signaling had 
reduced phagocytic ability and thus could not effectively eliminate tumor cells (179). 
Additionally, myeloid cell-specific NF-κB inhibition in a melanoma chemotherapy model 
resulted in increased tumor necrosis and mortality instead of tumor regression in 
response to doxorubicin. Tumors in mice with inhibited NF-κB signaling were rapidly 
populated by IL-1β-producing neutrophils, which sustained inflammation and facilitated 
necrosis (180). Thus, the effect of NF-κB inhibition in myeloid cells on carcinogenesis 
seems to be organ and/or context-dependent. Further study is necessary to understand 
differential responses to myeloid cell-specific NF-κB inhibition in different cancer models. 
 
Summary and dissertation goals 
 
The American Cancer Society estimated that over 220,000 Americans would be 
diagnosed with lung cancer in 2015, and another 158,000 would die from this disease 
(3). Despite significant advances in personalized therapy for lung cancer patients with 
targetable driver mutations in their tumor cells, benefits from each targeted therapy 
administered last at most a few months, and patients will eventually succumb to their 
disease as a result of tumor resistance to therapy (41, 53). In recent years, targeting 
cancer-related inflammation and modulating the immune system has received attention 
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as a potential alternative approach to treating lung and other cancers (54). The NF-κB 
pathway is a master regulator of inflammation and is activated in most cancers, including 
lung cancer. While it is known to play critical roles in promoting proliferation and survival 
of mutated lung epithelial cells, treatment of NSCLC patients with NF-κB inhibitors has 
not been effective. Myeloid cells are highly plastic cells that can be polarized toward anti- 
or pro-tumorigenic phenotypes in response to different signals from the 
microenvironment. The role of NF-κB signaling in myeloid cells during carcinogenesis is 
not fully understood, and it appears to be organ- and/or context-dependent.  
The goals of this dissertation were to determine the role of NF-κB signaling in 
myeloid cells during lung tumorigenesis and to identify novel therapeutic targets for the 
treatment of NSCLC. Our studies demonstrate that inhibition of NF-κB specifically in 
myeloid cells results in enhanced lung inflammation and tumorigenesis, providing a 
rationale for why NF-κB-targeted therapies are ineffective for lung cancer treatment. We 
determined that pro-IL-1β processing by neutrophils is a critical pathway of immune-
mediated chemoresistance to NF-κB inhibitors, which can be overcome using 
combination therapy with inhibitors of NF-κB and IL-1 signaling. Collectively, our findings 
show that NF-κB inhibitors are ineffective for lung cancer therapy due to the pro-
tumorigenic effects of NF-κB inhibition in myeloid cells. Our studies suggest that 
combined biological interventions targeting the NF-κB pathway and myeloid cell-derived 
pro-tumorigenic mediators could be beneficial in lung cancer patients. 
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CHAPTER II: MATERIALS AND METHODS 
 
Ethics statement 
 
All animal care and experimental procedures were approved and conducted 
according to guidelines issued by the Vanderbilt University Institutional Animal Care and 
Use Committee. Human de-identified plasma samples from a phase II clinical trial of 
advanced NSCLC patients were a kind gift from Dr. Vassilis Georgoulias at the 
University General Hospital of Heraklion in Crete, Greece. 
 
Patient samples 
  
Twenty-eight chemotherapy-naïve patients with inoperable, locally-advanced 
(Stage IIIB) or metastatic (Stage IV) NSCLC were treated with bortezomib (1 mg/m2) as 
part of a phase II clinical trial performed at the University Hospital of Crete (Protocol 
NCT01633645). Bortezomib was administered alone for the first cycle of treatment. All 
subsequent treatment cycles contained bortezomib plus gemcitabine and cisplatin. 
Plasma samples were collected before, 1 hour, and 24 hours after the first dose of 
bortezomib (Day 0) as well as before and 24 hours after the second dose of bortezomib 
(Day 8).  
 
Mice 
 
Mice used for studies were 8 to 10 weeks old and both age- and sex-matched.  
 
IKKβΔmye mice (IKKβfl/fl; LysM-Cre) on the C57BL6/J background (181) were backcrossed 
to the FVB genetic background for 10 generations. Lung tumors in these mice were 
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induced by a single intraperitoneal (IP) injection of urethane (ethyl carbamate, 1 g/kg; 
Sigma-Aldrich, St. Louis, MO). Littermate IKKβfl/fl mice with wild-type (WT) NF-κB 
signaling (called WT in our studies) were used as controls. BAY 11-7082 (Cayman 
Chemical, Ann Arbor, MI) was delivered by IP injection at 10 mg/kg body weight as 
described (109), and bortezomib (Millenium, Cambridge, MA) was delivered by IP 
injection at 1 mg/kg as previously described (110). Mice were sacrificed at 1, 6, and 16 
weeks after urethane injection.  
 
LSL-KrasG12D mice on the C57BL6/J background (182) were backcrossed to the FVB 
genetic background for 10 generations. Lung tumors in these mice were induced using 
intratracheal (IT) injection of adeno-Cre (1.5 x 107 PFU, University of Iowa Carver 
College of Medicine). Mice were harvested at 8 weeks after adeno-Cre.  
 
Doxycycline (Dox)-inducible KrasG12D mice that express mutant KrasG12D in Clara cell 
secretory protein (CCSP)-positive airway epithelial cells [CCSP-rtTA (tet-O)- KrasG12D] 
were used for treatment studies (183). Lung tumors were established in these mice via 
consumption of dox (0.5 g/L) in drinking water for 4 weeks. Subsequently, mice were 
treated with dox plus bortezomib, IL-1 receptor antagonist (IL-1ra, also known as 
anakinra/Kineret®, 60 mg/kg/d; Amgen, Thousand Oaks, CA), bortezomib plus IL-1ra, or 
vehicle control for 4 weeks. 
 
Caspase-1 knockout (Casp1 KO) mice on the C57BL/6 background (B6N.129S2-
Casp1tm1Flv/J) were obtained from The Jackson Laboratory (Bar Harbor, ME). Lung 
tumors in Casp1 KO mice and WT C57BL/6 controls were induced by 4 weekly IP 
injections of urethane (1 g/kg) as previously described (84). Mice were euthanized at 4 
months after the first injection of carcinogen.  
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NF-κB reporter mice on the FVB genetic background were generated in our laboratory 
and express a green fluorescent protein (GFP)-luciferase fusion protein upon expression 
of an NF-κB-dependent promoter (184). When injected retro-orbitally with luciferin, NF-
κB activation can be detected using bioluminescent imaging. 
 
Bioluminescent imaging 
 
NF-κB reporter mice (184) were anesthetized and shaved over the chest prior to 
imaging. Luciferin (1 mg/mouse in 100 μL isotonic saline) was injected retro-orbitally, 
and mice were placed inside of a light-tight box housing an intensified charge-coupled 
device (ICCD) camera (IVIS 200; Xenogen, Alameda, CA) for imaging. Light emission 
from the mouse was detected as photon counts by the ICCD camera and customized 
with image processing hardware and software (Living Image software; Xenogen). The 
imaging duration selected was 30 s to prevent saturation of the camera during image 
acquisition. To perform quantitative analysis, a standard area over the mid-lung zone 
was defined, and the total integrated photon intensity over the area of interest was 
measured. 
 
Cell lines 
 
The murine Lewis lung carcinoma (LLC) cell line was purchased from American 
Tissue Culture Collection (ATCC, Rockville, MD). Cells were cultured in Dulbecco’s 
Modified Eagle Medium (DMEM; Gibco, BRL, Carlsbad, CA) supplemented with 10% 
fetal bovine serum (FBS; Sigma-Aldrich) and 1% penicillin-streptomycin (Pen Strep; 
Mediatech, Inc., Manassas, VA) at 37°C and 5% CO2. 
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Subcutaneous tumor formation and monitoring 
 
To establish subcutaneous tumors, 250,000 murine LLC cells were injected 
subcutaneously into the flanks of syngeneic C57BL/6 mice. Tumors were allowed to 
grow to a volume of 10 mm2, upon which treatment with bortezomib, IL-1ra, bortezomib 
plus IL-1ra, or vehicle control was initiated. Tumor volume was monitored every two 
days. For tumor volume, length and width measurements were obtained using Traceable 
digital calipers (Fisher Scientific), and volume was calculated using the formula 
 𝑉 =  
𝜋
6
 𝑓(𝑙𝑒𝑛𝑔𝑡ℎ ∙ 𝑤𝑖𝑑𝑡ℎ)
3
2  as previously described (185). 
 
Bronchoalveolar lavage (BAL) 
 
BAL was performed by flushing the lungs 3 times with 800 μL phosphate buffered 
saline (PBS). Total cell count was determined using a grid hemocytometer. Cell 
differentials were determined by counting 300 cells per Wright-Giemsa-stained 
cytocentrifuged slide. 
 
Histology 
 
At the time of sacrifice, lungs were perfused with PBS and fixed in 10% formalin 
(Thermo Fisher Scientific, Waltham, MA) or Bouin’s fixative solution (Sigma-Aldrich). 
After 24 hours of fixation, lungs were used for surface tumor counting and diameter 
measurements under a dissecting microscope by at least two experienced readers 
blinded to sample identifiers. Tumor diameters were measured using Fisherbrand 
Traceable digital calipers (Fisher Scientific). Lungs were then embedded in paraffin, 
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sectioned (5 μm), stained with hematoxylin and eosin (H&E), and analyzed by a 
pathologist blinded to the experimental groups for evaluation of tumor and atypical 
adenomatous hyperplasia (AAH) lesions in 3 separate sections cut at predetermined 
depths.  
 
Immunohistochemistry 
 
For proliferation and apoptosis analyses, lung sections were immunostained with 
antibodies against proliferating cell nuclear antigen (PCNA; Life Technologies, Carlsbad, 
CA) or cleaved caspase-3 (Cell Signaling, Beverly, MA). Proliferation and apoptosis 
indices were calculated by counting the number of positive cells per 40x field and 
averaged from 25 randomly chosen fields. For analysis of tumor-infiltrating blood 
vessels, lung sections were immunostained with anti-CD34 antibodies (clone MEC14.7; 
BioLegend, San Diego, CA). Blood vessel density in tumors was calculated as the 
number of CD34+ endothelial cells per square millimeter of tumor area.  
 
Lung single cell suspensions 
 
Lungs were perfused with PBS and digested in Roswell Park Memorial Institute 
(RPMI) medium (Gibco) supplemented with collagenase XI (0.7 mg/mL; Sigma-Aldrich) 
and type IV bovine pancreatic DNase (30 μg/mL; Sigma-Aldrich) for 40 minutes at 37°C. 
Digested lungs were homogenized through a 70 μm cell strainer to obtain single-cell 
suspensions. Treatment with RBC Lysis Buffer (BioLegend) was used to remove red 
blood cells.  
  
 
29 
 
Flow cytometry/Fluorescence-activated cell sorting (FACS) 
 
Single-cell suspensions were incubated with Fc receptor block (1 µg/1 x 106 
cells; BD Biosciences, Franklin Lakes, NJ) to reduce nonspecific antibody binding. The 
panel of antibodies used in these experiments included: CD45 - APC-Cy7, CD11b - 
V450, Gr1 - PerCP-Cy5.5 (all from BioLegend); Ly6C - FITC and Ly6G - PerCP-Cy5.5 
(BD Biosciences); CD4 - FITC and CD25 - APC (e-Bioscience, San Diego, CA); MPO - 
FITC (Abcam, Cambridge, MA). Cells were stained with 4′,6-diamidino-2-phenylindole 
(DAPI; Life Technologies) to exclude dead cells from analysis. Flow cytometry was 
performed using the BD LSR II flow cytometer (BD Biosciences), and data were 
analyzed with FlowJo software (TreeStar, Ashland, OR). For in vitro studies, CD11b+ 
cells were purified by magnetic separation using microbeads (Miltenyi Biotec, San 
Diego, CA) followed by FACS based on expression of Ly6G and Ly6C.  
 
Allogenic Mixed Leukocyte reaction (MLR) assay 
 
CD4+/CD25- effector T cells (Teff) were isolated from spleens of naïve FVB mice 
(1 x 105/well) and labeled with carboxyfluorescein succinimidyl ester (CFSE) fluorescent 
dye (5 μM; Life Technologies, Carlsbad, CA) to measure cell proliferation in response to 
allogeneic mature bone marrow-derived dendritic cells from C57BL/6 mice. Dendritic 
cells were generated by culturing bone marrow cells in DMEM (Gibco) supplemented 
with 10% FBS (Sigma-Aldrich), 1% Pen Strep (Mediatech), 2-ME (50 mM; Gibco), 
recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) (20 ng/mL; 
Miltenyi Biotec), and interleukin 4 (20 ng/mL; Miltenyi Biotec) for 7 days. Dendritic cells 
were matured starting on day 7 by incubation for 24 hours with lipopolysaccharide (LPS) 
(1 μg/mL; Sigma-Aldrich). The ratio between the dendritic cells and CD4+/CD25- Teff 
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cells was 1:10. The suppressive function of CD11b+/Ly6G+ lung neutrophils from 
IKKβΔmye mice was tested on the proliferation of CFSE-labeled Teff cells by flow 
cytometry. Dead cells were excluded from analysis based on staining with DAPI. 
 
Real-time polymerase chain reaction (RT-PCR) 
 
RNA from whole lung tissue or sorted myeloid cells was isolated using the 
RNeasy Mini kit (Qiagen, Valencia, CA). cDNA was generated using SuperScript III 
Reverse Transcriptase (Life Technologies) and then subjected to RT-PCR using SYBR 
Green PCR Master Mix (Life Technologies) and the StepOnePlusTM RT-PCR System 
(Applied Biosystems, Grand Island, NY). Relative mRNA expression in each sample was 
normalized to GAPDH and presented using the comparative Ct method (2ΔCt). Primer 
sequences utilized are listed in Table 1.   
Gene Forward Primer (5’3’) Reverse Primer (5’3’) 
G-CSF TTGGTGAGTGGGGTTGCCATAGGT TGCCCTCTTCTCATTTGTGCTCCT 
GM-CSF CGTTGGTGAGTGAGGGAGAGAGTT TGAAAGGCAGGGCAAGACAAGG 
IL-6 AAAGAGTTGTGCAATGGCAATTCT AAGTGCATCATCGTTGTTCATACA 
KC CCGAAGTCATAGCCACACTCAA GCAGTCTGTCTTCTTTCTCCGTTAC 
IL-1β GCAACTGTTCCTGAACTCAACT ATCTTTTGGGGTCCGTCAACT 
CatG GCCAATCGCTTCCAGTTCTAC GTGGGTGTTCACATTCTTACCC 
TNFα AAGCCTGTAGCCCACGTCGTA GGCACCACTAGTTGGTTGTCTTTG 
IL-12p35 TGGACCTGCCAGGTGTCTTAG CAATGTGCTGGTTTGGTCCC 
ICAM1 TGCCTCTGAAGCTCGGATATAC TCTGTCGAACTCCTCAGTCAC 
IFNγ GCGTCATTGAATCACACCTGA CTCGGATGAGCTCATTGAATGC 
iNOS CACCTTGGAGTTCACCCAGT ACCACTCGTACTTGGGATGC 
CCL2 TTAAAAACCTGGATCGGAACCAA GCATTAGCTTCAGATTTACGGGT 
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CCL5 ACCATGAAGATCTCTGCAGC TGAACCCACTTCTTCTCTGG 
CCL17 TGCTTCTGGGGACTTTTCTG CATCCCTGGAACACTCCACT 
VEGF TTACTGCTGTACCTCCACC ACAGGACGGCTTGAAGATG 
IL-10 ACCTGCTCCACTGCCTTGCT GGTTGCCAAGCCTTATCGGA 
Arg1 GATTGGCAAGGTGATGGAAG TCAGTCCCTGGCTTATGGTT 
GAPDH TGAGGACCAGGTTGTCTCCT CCCTGTTGCTGTAGCCGTAT 
Table 1: Primer sequences for detection of cytokines and chemokines in mouse tissue 
using real-time PCR. 
 
 
Cytokine protein expression 
 
G-CSF, GM-CSF, IFNγ, IL-4, IL-6, IL-10, IL-12p40, KC, CCL2, and CCL3 protein 
concentrations were measured in whole lung homogenates by the MILLIPLEX MAP 
Mouse Cytokine/Chemokine Panel (Millipore, Billerica, MA) and analyzed with 
MILLIPLEX® Analyst software (Millipore). Murine IL-1β protein was measured in whole 
lung homogenates and conditioned media by ELISA (R&D Systems, Minneapolis, MN). 
Murine vascular endothelial growth factor (VEGF) was measured in BAL fluid by ELISA 
(R&D Systems). Human plasma IL-1β, IL-8, and TNF were measured using the BDTM 
Cytometric Bead Array Human Enhanced Sensitivity Flex Sets (limits of detection were 
48.4 fg/mL, 69.9 fg/mL, and 67.3 fg/mL, respectively) (BD Biosciences), and IL-6 was 
measured using the BDTM Cytometric Bead Array Human Flex Set (limit of detection was 
1.6 pg/mL) (BD Biosciences). 
  
Bone marrow cell isolation 
 
Femurs were removed from mice and washed in ice cold PBS. The tips of the 
femurs were cut off, and the marrow was flushed out of each bone using a 10mL syringe 
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of PBS and a 25-gauge needle. After centrifugation, red blood cells were lysed using 
RBC Lysis Buffer (BioLegend). 
 
Western blot 
 
Whole cell lysates were prepared using CelLyticTM MT Cell Lysis Reagent 
(C3228; Sigma), separated by SDS-PAGE gel, transferred to nitrocellulose membrane, 
and probed with anti-IKKβ (10AG2; Novus Biologicals) and anti-β-actin (A5316; Sigma). 
Immunodetection was performed using the corresponding AlexaFluor-conjugated 
antibodies and the Odyssey Infrared Imaging System (LI-COR Biosciences). 
 
Bone marrow transplantation 
 
For transplantation studies, lethally-irradiated (9.5 Gy) recipient mice were 
injected with bone marrow cells (2 x 106 bone marrow cells/mouse in PBS) from sex-
matched, syngeneic donor mice. The recipient chimeric animals were then housed under 
specific pathogen-free (SPF) conditions with access to autoclaved food and pH2 water 
containing neomycin (100 mg/L; Sigma-Aldrich) and polymyxin B (10 mg/L; Sigma-
Aldrich). To deplete resident lung macrophages, reconstituted chimeras were 
anesthetized, intubated using a 1 mL syringe with a 6 mm-long, 22-gauge, over-the-
needle catheter (Abbocath-T, Venisystems, Mundelein, Illinois), and injected IT with 100 
µl of liposomal clodronate (dichloromethylene diphosphonic acid, Sigma-Aldrich) at 4 
weeks after transplantation. Chimeras were then housed under SPF conditions and used 
for lung tumor studies 3 weeks later. 
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Depletion or neutralization of neutrophils, macrophages, and IL-1ra 
 
For neutrophil depletion, 100 μg of anti-Ly6G antibodies (Clone 1A8, BioLegend) 
or IgG2a isotype control antibodies (BioLegend) were delivered by IP injection twice a 
week for the first six weeks after urethane injection. For macrophage depletion, 
liposomal clodronate (dichloromethylene diphosphonic acid, Sigma-Aldrich) or liposomal 
phosphate buffered saline (PBS) was delivered by IT injection as previously described 
(186). To block IL-1β signaling, mice were treated with IL-1ra or PBS (vehicle control) 
delivered by subcutaneously implanted Alzet osmotic pumps (DURECT Corp., 
Cupertino, CA) with an infusion rate of 0.5 μL/h for 2 weeks. After 2 weeks, osmotic 
pumps were replaced to complete a 4-week course of treatment. Pumps were loaded 
such that each mouse received 60 mg/kg/day of IL-1ra.   
  
In vitro inhibitor studies 
 
Equal numbers of neutrophils were seeded into 96-well plates. Cells were 
cultured for 1 hour in the presence of caspase-1 inhibitor Ac-YVAD-CMK (100 µM; N-
1330.0005; Bachem), neutrophil elastase and proteinase 3 inhibitor MeOSuc-APPV-
CMK (100 µM; CAS 65144-34-5; Santa Cruz Biotechnology), or cathepsin G inhibitor Z-
GLP-CMK (100 µM; 03CK00805; MP Biomedicals).  
 
Statistical analysis 
 
Data from mouse models were analyzed using the GraphPad Prism 5.0 software 
(GraphPad Software Inc., La Jolla, DA), and values are presented as mean ± SEM. Pair-
wise comparisons were made using Student’s t-tests. For experiments conducted over 
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several time points or with multiple comparisons, a two-way ANOVA with a Bonferroni 
post-test was used to determine differences among groups. p<0.05 was considered 
statistically significant. 
Data from the 28 chemotherapy-naïve NSCLC subjects were analyzed using R 
software version 3.1.2 (www.r-project.org) and are expressed as median (interquartile 
range) for continuous variables and frequencies (proportions) for categorical variables. 
IL-1β, IL-8, TNF, and IL-6 before and 24 hours after initial treatment were compared 
using Student’s t-test. Spearman correlation between baseline IL-1β and progression-
free survival time in months was analyzed. We further applied a multivariable linear 
regression model to adjust for both subjects’ age at baseline and performance status. 
Normality of residuals of the linear model was diagnosed, and log transformation on 
progression-free survival time was performed to correct non-normal residuals if needed. 
p<0.05 was considered statistically significant. 
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CHAPTER III: INHIBITION OF NF-ΚB SIGNALING IN MYELOID CELLS ENHANCES 
LUNG TUMORIGENESIS VIA IL-1β SIGNALING. 
The contents of this chapter have been published and are shared with permission under 
the CC BY-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/) 
 
Rationale 
 
 
The NF-κB pathway has become increasingly appreciated for its involvement in 
carcinogenesis as studies continue to uncover its roles in primary tumor growth, 
angiogenesis, and metastasis (187). In the lungs, NF-κB is activated in pre-malignant 
airway epithelial lesions, atypical adenomatous hyperplasia (AAH) lesions in the distal 
lungs, and invasive non-small cell lung cancer (NSCLC) (67). Based on this information, 
inhibition of the NF-κB pathway has been tested as a therapy for lung cancer (188). The 
proteasome inhibitor bortezomib, which blocks degradation of the inhibitor of NF-κB (IκB) 
as well as other proteins that are regulated by the proteasome, is the best-studied agent 
for inhibiting NF-κB in humans; however, bortezomib has not been efficacious for NSCLC 
treatment (101, 102). The mechanism of resistance to bortezomib and other NF-κB 
inhibitor therapies is not known. Despite the disappointing results to date, numerous 
clinical trials have been attempted or are currently under way to test various combinations 
of bortezomib and other agents for cancer treatment. Our goals for these studies were to 
determine why NF-κB inhibitors are ineffective for NSCLC and to identify new approaches 
to overcome resistance to NF-κB inhibitors.  
 Our group and others have shown that NF-κB signaling in lung epithelial cells is 
crucial for lung tumor formation. In mice, expression of a constitutively active form of IKKβ 
(which activates canonical NF-κB) in airway epithelium results in a >3-fold increase in lung 
tumor formation after treatment with chemical carcinogens (83). In addition, a variety of 
methods (blocking IκB degradation, knockdown of IKKβ, or p65/RelA deletion) have been 
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used to inhibit NF-κB signaling in lung epithelium and have revealed a requirement for NF-
κB signaling in genetic and carcinogen-induced models of lung adenocarcinoma resulting 
from oncogenic Kras expression (84, 86–88). While some studies have shown short-term 
lung tumor responses to NF-κB inhibition (108, 109), pharmacologic NF-κB inhibition has 
not shown definitive long-term benefit in lung cancer models. Highlighting the challenges 
of NF-κB inhibition, Xue et al. showed that murine lung tumors developed resistance to 
therapy within a few weeks after treatment with bortezomib or an inhibitor of IκBα 
phosphorylation (BAY 11-7082) (109). Additionally, we showed that prolonged treatment 
with bortezomib enhanced, not hindered, lung tumor formation in urethane-treated mice 
(110). While it is possible that tumor cells could develop intrinsic resistance to NF-κB 
inhibitors via the acquisition of additional mutations (109), this would likely translate into 
sporadic appearance of secondary resistance, as opposed to the uniform primary 
resistance to bortezomib observed in various solid tumors (101, 102). Based on these 
observations, we postulated that systemic NF-κB inhibition evokes a pro-tumorigenic 
response from a non-epithelial cell population that overrides the anti-tumor effects 
resulting from NF-κB inhibition in epithelial cells.  
Myeloid cells play important roles in both innate immunity and tumorigenesis (186, 
189, 190). It is now well-accepted that macrophages and neutrophils can act as pro- or 
anti-tumorigenic cells during tumorigenesis depending on signals that they receive from 
the tumor and the tumor stroma (113, 138). The role of NF-κB signaling in these cells 
during tumorigenesis is controversial and seems to be organ- and/or context-dependent. 
Some cancer models show that blocking NF-κB signaling in myeloid cells elicits a 
protective, anti-tumorigenic response (78, 176). Others show that myeloid-specific NF-κB 
inhibition is detrimental and pro-tumorigenic (179, 180). In tumor-associated 
macrophages, blocking NF-κB can result in an anti-tumorigenic phenotype (177, 178). On 
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the other hand, a recent study showed that blocking NF-κB signaling in macrophages 
impedes their ability to mount anti-tumorigenic responses against melanoma cells (179).  
For these studies, we postulated that inhibition of NF-κB signaling in myeloid 
cells could elicit pro-tumorigenic responses that limit the effectiveness of global 
(systemic) NF-κB inhibition. To test this hypothesis, we utilized a mouse model 
characterized by myeloid cell-specific deletion of IKKβ (IKKβΔmye mice; LysM-
Cre/IKKβflox/flox) (181). Although these mice lack canonical NF-κB signaling in myeloid 
cells, including macrophages and neutrophils, in some settings they have enhanced 
inflammatory responses (191). In carcinogen-induced and genetic lung cancer models, 
we found that blocking NF-κB signaling in myeloid cells enhances lung tumorigenesis 
through neutrophil-dependent production of IL-1β and that combined NF-κB and IL-1β 
targeted treatments reduces tumor formation and growth. 
 
Results 
 
Neutrophils enhance lung tumorigenesis when NF-κB is inhibited in myeloid cells 
 
To determine the role of NF-κB signaling in myeloid cells during lung 
tumorigenesis, IKKβΔmye mice were fully back-crossed (>9 generations) to the tumor-
susceptible FVB background. Deletion of IKKβ in myeloid cells in the bone marrow 
compartment was confirmed by western blot (Figure 9).  
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Figure 9: IKKβ is deleted in bone marrow cells of IKKβΔmye mice. 
Expression of IKKβ protein by western blot in bone marrow cells from WT 
and IKKβΔmye mice showing deletion of IKKβ in IKKβΔmye mice. 
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Subsequently, IKKβΔmye mice and WT littermate controls were given a single IP injection 
of the carcinogen urethane (1 g/kg). Urethane causes lung tumors primarily through 
induction of Kras mutations (192), but it can also induce a number of other driver 
mutations found in human cancers (193). At week 16 after injection of urethane, we 
found that IKKβΔmye mice developed approximately twice as many lung tumors as WT 
mice (Figure 10A-B), indicating that inhibiting NF-κB signaling in myeloid cells promotes 
lung tumorigenesis. To determine if differences were detectable at an earlier stage of 
carcinogenesis, we harvested lungs at 6 weeks after urethane injection and identified a 
greater number of AAH lesions in lungs of IKKβΔmye mice compared to WT mice (Figure 
10D). Unexpectedly, at 6 weeks post-urethane, we observed some fully formed tumors 
in the lungs of IKKβΔmye mice (Figure 10C). On lung sections, 58% (7/12) of IKKβΔmye 
lungs contained adenomas at 6 weeks post-urethane compared with 7.1% (1/14) of WT 
lungs (p<0.01 by Fisher’s exact test). To investigate the mechanism of enhanced 
tumorigenesis in IKKβΔmye mice, we performed immunohistochemistry for markers of 
proliferation (PCNA) and apoptosis (cleaved caspase-3). Although we did not observe 
any differences in cleaved caspase-3 staining between IKKβΔmye and WT lungs, there 
were significantly more PCNA+ lung epithelial cells in IKKβΔmye mice compared to WT 
mice (Figure 10E-F and data not shown). To corroborate our findings from the 
urethane model, we utilized the LSL-KrasG12D (Kras) lung tumor model (182). We 
performed bone marrow transplantation in Kras mice using either WT (WTKras) or 
IKKβΔmye (IKKβΔmyeKras) donors. Lung tumors were induced in these bone marrow 
chimeras by IT injection of adenoviral vectors expressing Cre recombinase (adeno-Cre). 
Similar to urethane-injected IKKβΔmye mice, IKKβΔmyeKras mice developed twice as 
many lung tumors as WTKras mice at 8 weeks after adeno-Cre treatment (Figure 
10G-H). Together, these studies show that blocking NF-κB signaling in myeloid cells 
promotes lung tumorigenesis is both chemical and genetic models of lung cancer. 
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Figure 10: Inhibition of NF-κB signaling in myeloid cells increases lung tumorigenesis and 
epithelial cell proliferation. 
A) Representative photomicrographs and B) Number of lung tumors in WT and IKKβΔmye mice at 16 
weeks after a single injection of urethane (n=16-22 mice per group). C) Representative 
photomicrographs showing an AAH lesion (red arrow) in the lung of WT mice or tumor in IKKβΔmye 
mice, and D) Number of AAH lesions counted per H&E-stained lung section (3 sections per mouse) 
from WT and IKKβΔmye mice harvested at week 6 after injection of urethane (n=9-10 mice per group). 
E) Immunostaining for PCNA+ cells and (F) Number of PCNA+ cells per lung section (averaged from 
25 sequential fields taken at 40x magnification) from WT and IKKβΔmye mice harvested at week 6 after 
urethane injection (n=3-4 per group). G-H) Lethally-irradiated LSL-KrasG12D mice received bone 
marrow from WT (WTKras) or IKKβΔmye (IKKβΔmyeKras) mice. Lung tumors were induced by 
instillation of IT adeno-Cre (1.5x107 PFU). G) Representative photomicrographs and H) Number of 
lung tumors in WTKras and IKKβΔmyeKras mice at 8 weeks after adeno-Cre (n=4-9 mice per 
group) *p < 0.05 by Student’s t-test. 
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Since NF-κB is an important regulator of inflammation, we next investigated the 
role of myeloid NF-κB signaling on lung inflammation during tumorigenesis. No 
differences in inflammatory cells in BAL fluid were observed between untreated WT and 
IKKβΔmye mice; however, at 6 weeks post-urethane injection, we observed increased 
inflammatory cells in BAL from IKKβΔmye mice, indicating that heightened lung 
inflammation in IKKβΔmye mice was an effect of carcinogen treatment (Figure 11A). To 
evaluate specific myeloid subpopulations, we performed flow cytometry on lung cells 
from IKKβΔmye and WT mice (Figure 11B). Consistent with findings in BAL, no 
differences in neutrophil, monocyte, or macrophage cell populations were observed 
between untreated WT and IKKβΔmye mice (Figure 11C). In contrast, we found elevated 
numbers of neutrophils in the lungs of IKKβΔmye mice at 6 weeks post-urethane injection 
(Figure 11D). Additional studies in Kras model bone marrow chimeras showed similar 
findings with increased lung neutrophils in IKKβΔmyeKras mice at 8 weeks after IT 
adeno-Cre injection compared to WTKras mice (Figure 11E-F).  
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Figure 11: Neutrophils are increased in the lungs of mice lacking myeloid NF-κB signaling. 
A) Number of total BAL cells in WT and IKKβΔmye mice at baseline (C) and at 6 weeks after urethane 
injection (U) (n=7-9 mice per group; *p < 0.05 by one-way ANOVA compared with urethane-treated WT 
mice). B) Representative FACS plots and (C-D) Percentages of viable CD45+/CD11b+/Gr1hi neutrophils 
(Gr1hi), CD45+/CD11b+/Gr1low monocytes (Gr1low), and CD45+/CD11b+/Gr1neg macrophages (Gr1neg) in 
the lungs of WT and IKKβΔmye mice at (C) baseline and (D) 6 weeks after urethane injection (n=4-11 mice 
per group; *p < 0.05 by two-way ANOVA compared with WT). E) Representative FACS plots and (F) total 
viable CD45+/CD11b+/Ly6G+ neutrophils in the lungs of WTKras and IKKβΔmyeKras mice 8 weeks 
after adeno-Cre (n=4 mice per group; *p < 0.05 by Student’s t-test compared with WTKras). Ly6Ghi 
identifies the granulocytic subgroup of the Gr1 marker. 
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In order to determine if neutrophils were important for lung carcinogenesis, we 
performed neutrophil depletion using antibodies against Ly6G (194). WT and IKKβΔmye 
mice were injected with urethane and administered anti-Ly6G antibodies or isotype 
control IgG antibodies (100 μg) twice weekly for 6 weeks. A marked reduction in lung 
neutrophils was confirmed by flow cytometry (Figure 12A-B). While neutrophil depletion 
significantly reduced AAH lesions in lungs of IKKβΔmye mice, we observed no effect of 
this treatment in WT mice (Figure 12C). Next, we tested the effect of early neutrophil 
depletion on lung tumor formation. A bone marrow transplantation study was 
incorporated into this experiment to verify that enhanced tumorigenesis in IKKβΔmye mice 
was due to bone marrow-derived leukocytes in this model. Lethally-irradiated WT mice 
received bone marrow from IKKβΔmye (IKKβΔmyeWT) or WT (WTWT) donors. Bone 
marrow chimeras were injected with urethane and administered anti-Ly6G antibodies or 
isotype control IgG antibodies (100 μg) twice weekly for 6 weeks. At week 16 after 
urethane injection, we observed increased tumor formation in the lungs of control IgG-
treated IKKβΔmyeWT mice compared to control (IgG-treated) WTWT mice, indicating 
that enhanced tumorigenesis in IKKβΔmye mice was due to bone marrow-derived cells. 
Neutrophil depletion in anti-Ly6G antibody-treated IKKβΔmyeWT mice reduced lung 
tumor numbers compared to IgG-treated IKKβΔmyeWT mice, identifying neutrophils as 
key players during early lung carcinogenesis (Figure 12D). 
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Figure 12: Neutrophils promote lung tumorigenesis in the absence of myeloid NF-κB 
signaling. 
All mice were treated with isotype control IgG or anti-Ly6G depletion antibodies (100 μg by IP 
injection) for the first 6 weeks following urethane injection. A) Representative FACS plots and (B) 
total viable CD45+/CD11b+/Ly6C+/Ly6G+ lung neutrophils demonstrating depletion efficiency in 
IKKβΔmye mice harvested 3 days after the last dose of antibody (n=4 mice per group; *p < 0.05 by 
Student’s t-test). C) Number of AAH lesions per lung section from IgG- and anti-Ly6G-treated WT 
and IKKβΔmye mice at 6 weeks after urethane injection (n=6-9 mice per group; *p < 0.05 by one-
way ANOVA). D) Lethally-irradiated WT mice received bone marrow from WT or IKKβΔmye mice. 
Lung tumors at 16 weeks after urethane injection in bone marrow chimera mice treated with IgG 
or anti-Ly6G antibodies for the first 6 weeks of tumorigenesis (n=6-8 mice per group; *p<0.05 by 
one-way ANOVA). 
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Myeloid-specific NF-κB inhibition results in increased IL-1β production by neutrophils 
following carcinogen exposure  
 
To determine how IKKβ-deficient neutrophils exert their pro-tumorigenic effects 
during lung carcinogenesis, we characterized neutrophils from IKKβΔmye and WT mice 
according to morphological appearance, maturity, and function. We sorted 
CD45+/CD11b+/Ly6C+/Ly6G+ neutrophils (referred to below as Ly6G+ cells), 
CD45+/CD11b+/Ly6C+/Ly6G- monocytes, and CD45+/CD11b+/Ly6C-/Ly6G- macrophages 
using fluorescence-activated cell sorting (FACS) from lungs of urethane-treated IKKβΔmye 
and WT mice. Morphometric analysis of these cells confirmed that Ly6G+ cells had 
segmented nuclei, characteristic of mature neutrophils (Figure 13A). As early as 1 week 
post-urethane, IKKβΔmye mice had a nearly 3-fold increase in Ly6G+ cells in the lungs 
compared to WT mice, while lung monocytes and macrophages, as well as  peripheral 
blood neutrophils, were comparable between groups (Figure 13B and data not shown). 
To determine if loss of NF-κB signaling affected maturation of neutrophils, we measured 
expression of myeloperoxidase (MPO), an enzyme produced by mature neutrophils, in 
Ly6G+ cells from IKKβΔmye and WT mice at 1 week after urethane injection (Figure 13C). 
Loss of NF-κB signaling in Ly6G+ cells from IKKβΔmye mice did not impair MPO 
production (Figure 13C-D). We also examined N1/N2 markers in lung neutrophils by 
real-time PCR but did not observe differences in anti-tumorigenic N1 markers (TNFα, IL-
12p35, ICAM1, IFNγ, iNOS) or pro-tumorigenic N2 markers (CCL2, CCL5, CCL17, 
VEGF, IL-10, Arg1) between neutrophils from urethane-injected WT and IKKβΔmye mice 
(Figure 13E-F). Since a subset of Ly6G+ cells [granulocytic myeloid derived suppressor 
cells (MDSCs)] has been shown to promote tumorigenesis through suppression of anti-
tumor responses from T lymphocytes (195), we assessed the ability of Ly6G+ cells 
isolated from lungs of urethane-treated IKKβΔmye mice to suppress effector T (Teff) cell 
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proliferation in an allogeneic mixed lymphocyte reaction assay. As shown in Figure 13G, 
Ly6G+ cells from IKKβΔmye mice failed to suppress proliferation of Teff cells stimulated by 
allogeneic dendritic cells, indicating that Ly6G+ cells from IKKβΔmye mice do not act as 
MDSCs. These studies show that Ly6G+ neutrophils from IKKβΔmye mice are mature cells 
that are not highly polarized towards N1 or N2 and do not exhibit immunosuppressive 
properties during early lung tumorigenesis. 
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Figure 13: Mature neutrophils are increased in the lungs during early tumorigenesis in the 
absence of myeloid NF-κB signaling. 
A) FACS sorting strategy and photomicrographs demonstrating cell morphology of lung monocytes 
(CD45+/CD11b+/Ly6C+/Ly6G-) and neutrophils (CD45+/CD11b+/Ly6C+/Ly6G+) isolated from lungs of 
WT and IKKβΔmye mice at 1 week after urethane injection. B) Numbers of CD11b+/Ly6G+ neutrophils 
(Ly6G+), CD11b+/Ly6C+ monocytes (Ly6C+), and CD11b+/Ly6Gneg/Ly6Cneg macrophages (Ly6G/Cneg) 
in the lungs of WT and IKKβΔmye mice at 1 week after urethane injection (n=3 mice per group, 
representative of 2 independent experiments; *p<0.05 compared to WT by two-way ANOVA). C) 
Flow cytometry plot (including fluorescence minus one [FMO] control) and (D) mean fluorescence 
intensity (MFI) showing expression of MPO in viable CD45+/CD11b+/Ly6G+ cells from lungs of WT 
and IKKβΔmye mice at 1 week after urethane injection (n=4 mice per group). Expression of (E) N1 and 
(F) N2 markers in CD45+/CD11b+/Ly6G+ cells isolated from lungs of IKKβΔmye mice at 1 week after 
urethane injection (n=4-5 mice per group). G) CD45+/CD11b+/Ly6G+ cells isolated from lungs of 
IKKβΔmye mice at 1 week after urethane injection do not impair the ability of allogeneic dendritic cells 
(DC) to induce proliferation of CFSE-labeled responder CD4+/CD25- T cells (Teff) (1:1, performed in 
duplicate).  
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Since we did not identify differences in maturation or function of neutrophils from 
IKKβΔmye mice, we investigated whether differential production of inflammatory mediators 
could be responsible for increased tumorigenesis in the context of NF-κB inhibition. We 
measured mRNA and protein expression of a panel of cytokines (G-CSF, GM-CSF, 
IFNγ, IL-1β, IL-4, IL-6, IL-10, IL-12p40, KC, CCL2, and CCL3) in the lungs of IKKβΔmye 
and WT mice at 1 week after urethane injection. Both KC mRNA and protein were 
increased in lungs of IKKβΔmye mice, while IL-1β protein, but not mRNA, was upregulated 
(Figure 14A-B). For IL-1β, increased protein without increased mRNA expression 
suggests increased pro-IL-1β processing, which has previously been shown to occur in 
the setting of NF-κB inhibition (191). No differences in IL-1β protein levels were detected 
between untreated WT and IKKβΔmye mice (data not shown). To determine the cellular 
source for increased IL-1β protein in IKKβΔmye mice, we sorted myeloid cells from lungs 
at 1 week after urethane injection and measured IL-1β in conditioned media. Neutrophils 
from IKKβΔmye mice secreted nearly twice as much IL-1β as monocytes or macrophages 
(Figure 14C) and produced more IL-1β than lung neutrophils from urethane-injected WT 
mice (Figure 14D), identifying IKKβ-deficient neutrophils as the source of increased IL-
1β protein levels in the lungs. To verify that neutrophils were the primary source of IL-1β, 
we performed macrophage and neutrophil depletion studies in urethane-treated IKKβΔmye 
mice. For macrophage depletion, urethane-treated IKKβΔmye mice were administered 
liposomal clodronate or vehicle (liposomal PBS) by IT injection (186) and harvested at 1 
week after urethane. Macrophage depletion did not alter IL-1β protein in the lungs of 
IKKβΔmye mice (Figure 14E). For neutrophil depletion, urethane-treated IKKβΔmye mice 
received IP injections of 100 μg of anti-Ly6G or isotype control IgG antibodies (130, 196) 
and lungs were harvested 1 week later. Neutrophil depletion was confirmed by flow 
cytometry, showing a reduction in the percentage of Ly6G+ cells within the 
CD45+/CD11b+ gate from 45.2±2.9% in mice treated with control IgG antibodies to 
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1.0±0.6% in mice treated with anti-Ly6G antibodies (p<0.0001). Compared to IKKβΔmye 
mice treated with control IgG antibodies, anti-Ly6G antibody treatment significantly 
reduced IL-1β in the lungs (Figure 14F). Taken together, these studies point to IL-1β as 
a neutrophil-derived mediator that could support enhanced lung tumorigenesis. 
Serine proteases have been implicated in the regulation of IL-1β processing by 
neutrophils (191); therefore, we performed inhibitor studies to determine the mechanism 
of dysregulated IL-1β release by lung neutrophils from IKKβΔmye mice. Lung neutrophils 
were isolated from urethane-treated WT and IKKβΔmye mice and cultured in the presence 
of inhibitors of caspase-1 (Ac-YVAD-cmk; YVAD), neutrophil elastase and proteinase 3 
(MeOSuc-APPV-CMK; MeO), or cathepsin G (Z-GLP-CMK; GLP). While caspase-1 
inhibition partially reduced IL-1β release from IKKβΔmye neutrophils, inhibition of the 
serine protease cathepsin G blocked nearly all IL-1β secretion from neutrophils of both 
WT and IKKβΔmye mice (Figure 14G). Additionally, gene expression of cathepsin G was 
upregulated in lung neutrophils from urethane-treated IKKβΔmye mice compared to WT 
mice, while no differences in expression were observed in caspase-1, neutrophil 
elastase, or proteinase 3 (Figure 14H and data not shown). These data implicate 
cathepsin G as the primary regulator of IL-1β processing by lung neutrophils in urethane-
treated mice. 
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Figure 14: Neutrophils from IKKβΔmye mice produce increased IL-1β following urethane 
injection. 
Expression of cytokines by A) mRNA and B) protein in the lungs of WT and IKKβΔmye mice harvested 
1 week after urethane (n=10-11 mice per group; *p < 0.05 compared with WT by Student’s t-test). C) 
Concentration of IL-1β in the conditioned media following 12-hour culture of lung Ly6G+ neutrophils, 
Ly6C+ monocytes, or Ly6G/Cneg macrophages isolated from IKKβΔmye mice at 1 week after urethane 
injection (n=3; *p < 0.05 by one-way ANOVA compared with Ly6C+ and Ly6G/Cneg). D) Concentration 
of IL-1β in the conditioned media following 12-hour culture of lung Ly6G+ neutrophils from WT and 
IKKβΔmye mice at 1 week after urethane injection (n=8 mice per group; *p < 0.05 by Student’s t-test). 
E) IL-1β protein levels in lung homogenates at 1 week after urethane in the lungs of IKKβΔmye mice 
treated with liposomal clodronate or PBS on day 5 following urethane injection (n=6 mice per group). 
F) IL-1β protein levels at 1 week after urethane in the lungs of IKKβΔmye mice treated with anti-Ly6G 
antibodies (100 μg) or control IgG antibodies by IP injection on days -1, 2, and 5 relative to the day of 
urethane injection (n=3-5 mice per group; *p < 0.05 *p < 0.05 by Student’s t-test compared with 
IKKβΔmye mice treated with control IgG antibodies). Lung Ly6G+ neutrophils were isolated from WT 
and IKKβΔmye mice at 1 week after urethane injection. G) IL-1β concentration in the conditioned media 
after culture with inhibitors (all 100 μM) of caspase-1 (Ac-YVAD-CMK), neutrophil elastase and 
proteinase-3 (MeOSuc-APPV-CMK), or cathepsin G (Z-GLP-CMK) (n=3-8 replicates per group; 
#p>0.05 compared to WT Unt; *p<0.05 by two-way ANOVA compared to either WT or IKKβΔmye Unt). 
H) mRNA expression of cathepsin G in lung Ly6G+ neutrophils isolated from WT and IKKβΔmye mice at 
1 week after urethane injection (n=5 mice per group; *p < 0.05 by Student’s t-test) 
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Systemic NF-κB inhibition increases IL-1β production in mice and humans with lung 
cancer  
 
We next sought to determine whether IL-1β dysregulation could be detected 
following treatment with pharmacological NF-κB inhibitors in mice and human NSCLC 
patients. WT mice were treated with the proteasome inhibitor bortezomib (1 mg/kg) (109, 
110) or vehicle by IP injection on days 2 and 6 following urethane injection and 
harvested at day 7 (Figure 15A). We observed elevated numbers of neutrophils in BAL 
from bortezomib-treated mice compared to vehicle-treated controls (Figure 15B). In 
addition, we found increased IL-1β protein in both serum and lungs of bortezomib-
treated mice compared to mice treated with vehicle (Figure 15C-D). To test whether 
these effects were common to different classes of NF-κB inhibitors, we repeated our 
studies using BAY 11-7082 (BAY). NF-κB inhibition was verified by luciferase activity as 
a measure of NF-κB activity in vehicle- or BAY-treated NF-κB reporter mice (184) after 
urethane injection (Figure 16). At 1 week after urethane injection, BAY treatment 
resulted in increased neutrophils in BAL and lung tissue (Figure 15E-G). BAY-treated 
mice also had elevated IL-1β protein in lung homogenates compared to vehicle-treated 
mice, similar to IKKβΔmye mice (Figure 15H). Unlike IKKβΔmye mice, however, KC 
expression was not increased in BAY-treated WT mice (Figure 17). 
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Figure 15: Pharmacological inhibition of NF-κB increases IL-1β in mice. 
A) Schematic representation of NF-κB inhibition protocol using bortezomib (Bort). In addition to urethane, 
WT mice were treated with IP injections of Bort (1 mg/kg) or vehicle control (Veh). B) BAL cells in Bort- or 
Veh-treated WT mice at 1 week after urethane injection (n=4-5 mice per group; *p<0.05 by Student’s t-
test compared to Veh). C) Serum and (D) lung IL-1β protein levels from Bort- or Veh-treated WT mice 1 
week after urethane (n=6 mice per group; *p<0.05 by Student’s t-test compared to Veh). E) Schematic 
representation of the NF-κB inhibition protocol using BAY 11-7082 (BAY). In addition to urethane, WT 
mice were treated with IP injections of the specific NF-κB inhibitor BAY (10 mg/kg) or Veh. F) BAL cells in 
BAY- and Veh-treated WT mice at 1 week after urethane injection (n=8 mice per group). G) Number of 
Ly6G+ neutrophils and Ly6C+ monocytes in the lungs of BAY- or Veh-treated mice at 1 week after 
urethane injection (n=4-5 mice per group; *p<0.05 by Student’s t-test compared to Veh). H) IL-1β protein 
levels in the lungs of BAY- or Veh-treated mice at 1 week after urethane injection (n=8 mice per group; 
*p<0.05 by Student’s t-test compared to Veh). 
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Figure 16: BAY 11-7082 treatment blocks NF-κB activation in reporter mice. 
NF-κB reporter mice were injected with a single dose of urethane and treated with BAY 11-7082 
(10 mg/kg by IP injection) or vehicle control 3 times per week. Chest bioluminescence was 
measured at baseline (prior to urethane treatment) and 10 days after urethane injection (RLU = 
relative light units).  NF-κB reporter mice that express a green fluorescent protein-luciferase 
fusion protein under control of an NF-κB dependent promoter were injected intravenously with D- 
luciferin (1 mg) followed by bioluminescent imaging (n=3-5 mice per group; *p<0.05 by Student’s 
t-test compared to Veh). 
Figure 17: KC expression is not increased upon systemic NF-κB inhibition in WT mice. 
Expression of cytokines by mRNA in the lungs of IKKβΔmye mice injected with urethane and 
treated with BAY 11-7082 (10 mg/kg) or vehicle control (Veh) for 1 week (n=8 mice per group). 
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To investigate the relevance of our mouse model findings to human NSCLC, we 
obtained blood samples from a completed study involving 28 chemotherapy-naïve 
individuals with advanced stage (III-IV) NSCLC (protocol NCT01633645) (Table 2). In 
this study, patients received one cycle of bortezomib followed by a standard 
chemotherapy/bortezomib combination regimen. In plasma obtained before and 24 
hours after the first dose of bortezomib (1 mg/m2), we measured a panel of cytokines (IL-
1β, IL-8, TNF, and IL-6) using cytometric bead array and found that treatment with 
bortezomib significantly increased IL-1β protein in the plasma of advanced NSCLC 
patients; however, no differences were detected in IL-8, TNF, or IL-6 (Figure 18A-D). In 
addition, we found that after controlling for age and performance status, IL-1β level at 
baseline significantly correlated with reduced progression-free survival in this cohort 
(p=0.026) (Figure 18E).  
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Patient Characteristics Total (n=28) 
Age, y 75.5 (68.5, 79.2)* 
Male gender 22 (78.6%)† 
Cancer stage  
IIIB 1 (3.6%)† 
IV 27 (96.4%)† 
Cancer histology  
Adenocarcinoma 11 (39.3%)† 
Squamous 11 (39.3%)† 
Other NSCLC 6 (21.4%)† 
Performance score  
0 19 (67.9%)† 
1 9 (32.1%)† 
Progression-free survival, mo 3.6 (1.7, 6.4)* 
Overall survival, mo 10.2 (4.7, 21.0)* 
Table 2: Characteristics of NSCLC patients treated with bortezomib. 
*  Data are represented as median (interquartile range) 
†  Data are represented as total (percent) 
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Figure 18: Bortezomib treatment increases plasma IL-1β and indicates worse 
survival in NSCLC patients. 
A) IL-8, (B) TNF, (C) IL-6, and (D) IL-1β protein levels in the plasma of NSCLC patients 
treated before (0hr) and 24hr after treatment with bortezomib (1 mg/m2) (n=28 patients; 
*p < 0.05 by Student’s t-test compared with 0 hr). E) Correlation analysis between 
progression-free survival and baseline plasma IL-1β protein levels in advanced NSCLC 
patients treated with bortezomib plus standard chemotherapy (p=0.026 by adjusted 
Spearman’s correlation). 
57 
 
IL-1β promotes lung tumorigenesis, enhances epithelial cell proliferation, and mediates 
resistance to NF-κB inhibitor therapy  
 
Since IL-1β production is increased in tumor models in the setting of myeloid and 
systemic NF-κB inhibition, we investigated the impact of IL-1β on lung tumorigenesis 
using the clinically available IL-1 receptor antagonist (IL-1ra, anakinra/Kineret®). IL-1ra 
(60 mg/kg/day) was delivered during the first 4 weeks after urethane injection to WT and 
IKKβΔmye mice using subcutaneously implanted osmotic pumps (Figure 19A). Osmotic 
pumps filled with PBS were used as controls. Effective drug delivery was indicated by 
reduced BAL neutrophils as well as reduced expression of IL-1 signaling targets KC, 
CXCL5, and IL-1β in the lungs at 1 week after urethane injection (Figure 19B-C). As 
shown in Figure 19D, IL-1ra treatment significantly decreased the number of AAH 
lesions in the lungs of IKKβΔmye mice at 6 weeks after urethane injection. To evaluate the 
impact of IL-1β signaling on tumor formation, we repeated these studies and harvested 
mice 16 weeks after urethane treatment. We found that IL-1ra treatment reduced lung 
tumors in IKKβΔmye mice by more than 50% compared to IKKβΔmye mice treated with PBS 
control (Figure 19E). Based on our finding that IKKβΔmye mice have increased lung 
epithelial cell proliferation during tumorigenesis (Figure 10E-F), we tested whether IL-1β 
could exert its pro-tumorigenic effects by altering proliferation of epithelial cells. We 
performed PCNA immunostaining on lung sections from IL-1ra- and PBS-treated 
IKKβΔmye mice harvested 6 weeks after urethane and found reduced PCNA+ lung 
epithelial cells in IL-1ra-treated IKKβΔmye mice (Figure 19F), demonstrating that IL-1β 
signaling supports epithelial cell proliferation during tumorigenesis. Together, these 
results indicate a pro-tumorigenic role for IL-1β in the setting of NF-κB inhibition in 
myeloid cells. 
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Figure 19: IL-1β facilitates lung tumorigenesis by stimulating epithelial 
cell proliferation 
A) Schematic representation of IL-1 receptor antagonist (IL-1ra) treatment 
protocol. WT and IKKβΔmye mice were injected with a single dose of urethane 
and treated by osmotic pump delivery of 60 mg/kg/day of IL-1ra or PBS for the 
first 4 weeks. B) Total BAL cells and (C) mRNA expression of cytokines in the 
lungs of urethane-injected IKKβΔmye mice treated with IL-1ra or PBS for 1 week 
(n=4-5 mice per group; *p<0.05 by Student’s t-test compared to PBS). D) 
Number of AAH lesions per H&E-stained lung section harvested from IKKβΔmye 
mice at week 6 after injection of urethane (n=9 mice per group, *p<0.05 by 
Student’s t-test compared with PBS). E) Lung tumors on H&E-stained lung 
sections from WT and IKKβΔmye mice cut at predetermined depths (5 sections 
per mouse, n=7 mice per group; *p<0.05 by one-way ANOVA compared with 
PBS-treated IKKβΔmye mice). F) Number of PCNA+ cells per lung section 
(averaged from 25 sequential fields taken at 40x magnification) from IKKβΔmye 
mice harvested at week 6 after urethane injection (n=9 mice per group; 
*p<0.05 by Student’s t-test compared with PBS). 
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Since IL-1β is dysregulated and supports tumor cell proliferation in the context of 
NF-κB inhibition, we next tested whether the addition of IL-1ra could improve the efficacy 
of NF-κB inhibitor therapy in two different lung cancer models. In the first model, we 
injected murine Lewis lung carcinoma (LLC) cells subcutaneously into the flanks of 
syngeneic WT mice. When tumors reached 1 cm in diameter, mice were divided into four 
treatment groups: bortezomib, IL-1ra, bortezomib plus IL-1ra, or vehicle control. 
Bortezomib (or vehicle) was administered by IP injection twice weekly, and IL-1ra (or 
PBS control) was administered throughout the treatment course via osmotic pump. 
Whereas monotherapy with bortezomib or IL-1ra did not affect tumor growth, 
combination therapy with bortezomib and IL-1ra significantly reduced tumor growth 
compared with all other groups at day 10 after initiating treatment (Figure 20).  
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Figure 20: Combination therapy with bortezomib and IL-1ra slows tumor growth. 
Fold change of subcutaneous LLC tumor volume over 10 days of treatment with vehicle control, 
bortezomib, IL-1ra, or bortezomib plus IL-1ra (n=6-9 mice per group; *p<0.05 by one-way ANOVA 
compared with control). 
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For the second model, we used doxycycline (dox)-inducible KrasG12D mice (183). 
In a preliminary study, we treated mice with dox for 4 weeks followed by bortezomib 
twice weekly for 1 week and found increased neutrophils in the lungs compared to 
vehicle-treated mice (Figure 21A). Subsequently, we treated inducible KrasG12D mice 
with dox for 4 weeks and then randomized mice to treatment with bortezomib, IL-1ra, 
bortezomib plus IL-1ra, or vehicle control for 4 additional weeks. While treatment with 
bortezomib reduced tumor numbers compared to vehicle control and IL-1ra groups, lung 
tumors were reduced by 90% in mice administered combination therapy with bortezomib 
and IL-1ra (Figure 21B-C). Collectively, our findings indicate that combination therapy 
with bortezomib and IL-1ra reduced tumor formation and growth, and was more effective 
than bortezomib alone. 
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Figure 21: Combination therapy with bortezomib and IL-1ra reduces tumor number in 
KrasG12D mice. 
A-C) Inducible KrasG12D mice were treated with doxycycline (dox) for 4 weeks to develop lung 
tumors. (A) Percentage of Ly6G+ and Ly6C+ cells in the lungs of dox-inducible KrasG12D mice 
treated for 1 additional week with Bort or Veh plus dox (*p<0.05 by Student’s t-test compared to 
Veh). (B) Numbers of surface lung tumors and (C) Representative photomicrographs of lung 
tumors in mice treated with dox alone for 4 weeks followed by 4 weeks of treatment with dox plus 
vehicle control, bortezomib, IL-1ra, or bortezomib plus IL-1ra (n=6-7 mice per group; *p<0.05 by 
one-way ANOVA compared with control. 
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Discussion 
 
 
Our studies identify IL-1β as a targetable, pro-tumorigenic mediator that 
contributes to resistance of lung tumors to NF-κB inhibitors. We showed that inhibition of 
NF-κB in myeloid cells enhances lung tumorigenesis and paradoxically increases 
infiltration of neutrophils into the lungs. NF-κB-deficient neutrophils produced elevated 
levels of IL-1β, which was regulated by the serine protease cathepsin G. Consistent with 
studies in mice with myeloid-specific NF-κB inhibition, systemic delivery of 
pharmacological NF-κB inhibitors to WT mice significantly increased lung neutrophils and 
IL-1β production during lung tumorigenesis. In humans with advanced stage NSCLC, 
plasma IL-1β concentration inversely correlated with progression-free survival and IL-1β 
levels were increased following treatment with the proteasome inhibitor bortezomib. 
Neutrophil depletion studies and pharmacological IL-1ra treatment, both of which reduced 
lung tumors in the setting of myeloid NF-κB inhibition, support a causative role for 
neutrophil-derived IL-1β in lung tumorigenesis. Further, we demonstrated that combined 
treatment with bortezomib and IL-1ra reduces tumor formation and growth in vivo and that 
IL-1β exerts its pro-tumorigenic effects by stimulating lung epithelial cell proliferation. In 
addition to demonstrating an important role for IL-1β in promoting lung carcinogenesis and 
mediating resistance to NF-κB inhibitors, these data provide support for use of rational 
combined biological therapies to treat lung cancer. 
Together with existing literature, our findings suggest that the lung 
microenvironment could support both pro- and anti-tumorigenic outcomes resulting from 
inhibition of NF-κB signaling. Consistent with our previous studies showing pro-
tumorigenic outcomes from long-term bortezomib treatment (110), these data 
demonstrate that inhibition of NF-κB signaling specifically in myeloid cells enhances lung 
tumorigenesis. Our findings are also in agreement with a recent report in which myeloid 
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NF-κB inhibition supported enhanced growth of melanomas (179). In opposition, previous 
studies using a colon cancer model and a model of lung cancer induced by oncogenic 
Kras plus cigarette smoke found that inhibition of NF-κB signaling in myeloid cells inhibited 
tumorigenesis (Greten et al., 2004; Takahashi et al., 2010). We suggest that differences 
in tumorigenic outcomes in response to myeloid-specific NF-κB inhibition may be due to 
differential effects on pre-existing inflammation in the tumor microenvironment. Both the 
azoxymethane plus dextran sulfate colon cancer model and the oncogenic Kras plus 
cigarette smoke model are highly inflammatory models in which myeloid NF-κB inhibition 
reduces carcinogenesis as well as cytokine expression and inflammatory cell infiltration 
(Greten et al., 2004; Takahashi et al., 2010). In contrast, the lung cancer models in our 
studies result in only mild inflammation, and myeloid NF-κB inhibition increases 
inflammation in these settings. Therefore, it may be that the overall impact of myeloid NF-
κB inhibition on tumorigenesis is dependent upon the inflammatory environment. In 
environments with high levels of pre-existing inflammation, inhibition of NF-κB signaling 
may reduce pro-tumorigenic inflammation by blocking transcription of NF-κB-dependent 
mediators, consequently suppressing tumor formation and growth. In contrast, up-
regulation of IL-1β processing by neutrophils may play an important pro-tumorigenic role 
in less inflammatory environments, which may be more similar to human lung cancer, by 
providing important proliferation signals to mutated epithelial cells. In either case, it may 
be that combination biological approaches to block inflammatory signaling are superior to 
NF-κB inhibition alone. 
In our studies, we discovered that neutrophils play critical roles during early lung 
tumor formation. We show that both myeloid-specific and systemic inhibition of NF-κB 
induces an increase in lung neutrophils, potentially through increased recruitment or 
prolonged cell survival, which has been previously described for NF-κB-inhibited 
neutrophils (197, 198). Depletion of neutrophils during early tumor initiation and promotion 
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stages reduced lung tumor formation in our model, consistent with previous reports using 
oncogenic Kras models, which showed reduced tumorigenesis with neutrophil depletion 
or genetic neutrophil elastase deficiency (199, 200). The N1/N2 neutrophil polarization 
paradigm has been used to explain anti- or pro-tumorigenic functions of neutrophils (130). 
Several studies have shown that N2 tumor-associated neutrophils exert their pro-
tumorigenic properties through production of angiogenic factors, matrix-degrading 
enzymes, and immunosuppression (Reviewed in Sionov et al., 2014). In contrast, our 
studies show that neutrophils with inhibited NF-κB signaling are not highly polarized 
towards N1 or N2 and are not immunosuppressive. Instead, NF-κB-deficient neutrophils 
have a unique pro-tumorigenic phenotype characterized by dysregulated processing of 
the inflammatory mediator IL-1β.  
 While we identified an important role for neutrophils in accelerating lung 
tumorigenesis in the context of NF-κB inhibition, other cell types may also contribute to 
this phenotype. Although not directly tested in our studies, interactions between 
neutrophils and macrophages may be important for creating a pro-tumorigenic 
environment in the lungs. This idea is supported by our previous finding that macrophages 
are important for urethane-induced tumorigenesis (186), as well as a recent study 
demonstrating that macrophages with inhibited NF-κB signaling are unable to mediate 
anti-tumor responses against metastatic melanoma cells (179). Future studies are 
necessary to fully elucidate interactions between inflammatory cell types and epithelial 
cells that regulate lung carcinogenesis. 
A connection between elevated IL-1β and lung cancer in humans has been 
suggested by studies showing that a single nucleotide polymorphism (-31C-T) in IL1B 
increases IL-1β expression and lung cancer risk (201, 202). Our studies extend these 
findings by showing that IL-1β levels in plasma were inversely correlated with progression-
free survival of NSCLC patients. Further, we found that plasma IL-1β levels of NSCLC 
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patients increase following NF-κB inhibition with the proteasome inhibitor bortezomib, 
suggesting that our explanation for resistance to NF-κB inhibitor therapy may be relevant 
to NSCLC patients.  
We found that both myeloid-specific and systemic NF-κB inhibition increase IL-1β 
protein expression in the lungs. Although IL-1β mRNA expression is regulated by the NF-
κB pathway (203), our findings are consistent with previous reports showing that NF-κB 
inhibition in myeloid cells increases IL-1β processing under conditions of septic shock and 
acute lung injury (191, 197, 204). While IL-1β processing in most cells is thought to be 
primarily regulated by the inflammasome, serine proteases have been implicated in IL-1β 
processing by neutrophils (191, 205). Our findings indicate that cathepsin G strongly 
regulates IL-1β production by neutrophils and that expression of cathepsin G is 
upregulated in neutrophils with inhibited NF-κB, potentially explaining the increased IL-1β 
production in this setting. Since cathepsin G has been correlated with tumor grade and 
clinical stage in NSCLC (206), future studies targeting this protease could be warranted.  
Our studies demonstrate that the addition of IL-1 signaling blockade to NF-κB 
inhibitor therapy improves the effectiveness of NF-κB inhibition to reduce lung tumor 
formation and growth. In a heterotopic flank tumor model, combination therapy was the 
only regimen that slowed tumor growth compared to vehicle control. In the dox-inducible 
KrasG12D model, bortezomib monotherapy reduced tumor formation but combination 
therapy with bortezomib and IL-1ra was most effective. These findings indicate that the 
effects of bortezomib are variable and model-dependent. In contrast, we consistently 
showed impressive responses to therapy with combination bortezomib/IL-1ra treatment. 
Of the 35 clinical trials included in the ClinicalTrials.gov database that investigate 
bortezomib in lung cancer, only three have used combined therapy with bortezomib and 
another targeted agent. Since combined targeted therapies may be the most direct way 
to manage disease and reduce nonspecific side effects from treatment (207), our studies 
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support future human studies combining NF-κB inhibitors with IL-1ra or other targeted 
biological therapies aimed at overcoming resistance mechanisms. 
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CHAPTER IV: CONCLUDING REMARKS 
 
Summary 
Together with existing literature, the work presented in this dissertation identifies 
separate roles for NF-κB signaling in epithelial and myeloid cells during lung 
carcinogenesis. NF-κB signaling in epithelial cells has been shown to promote 
tumorigenesis in a variety of lung cancer models through increased epithelial cell 
proliferation and/or survival (83, 84, 86–88). NF-κB signaling in myeloid cells, on the 
other hand, seems to play different roles during tumorigenesis depending on the degree 
of inflammation present in the lung microenvironment. When lung inflammation is robust, 
blocking myeloid NF-κB signaling appears to be protective by reducing destructive 
inflammatory signaling (176). However, our studies show that in a less inflammatory 
environment, which is more closely related to the low-grade inflammation commonly 
associated with cancer, blocking NF-κB signaling in myeloid cells supports pro-
tumorigenic inflammatory signaling. One important mechanism for tumor promotion in 
this context is dysregulation of IL-1β processing by neutrophils. The resulting elevated 
levels of mature IL-1β support tumorigenesis by increasing proliferation of epithelial 
cells. Combined inhibition of NF-κB and IL-1 signaling pathways impedes lung tumor 
formation and growth, representing the potential of combination therapies with NF-κB 
inhibitors and other agents for lung cancer treatment. 
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Additional data and future directions 
 
 
Role of myeloid NF-κB signaling in lung tumor angiogenesis 
 
In addition to discovering increased numbers of lung tumors in mice with myeloid 
cell-specific inhibition of NF-κB signaling, we also observed that the lung tumors in these 
mice were about half the size of those in WT mice at 16 weeks after urethane injection 
(Figure 22A). Since NF-κB is known to regulate angiogenesis, a process that is critical 
for continuous outgrowth of tumors (208–212), we performed immunostaining on lung 
sections for the endothelial cell marker CD34 to compare blood vessel density within 
tumors from WT and IKKβΔmye mice harvested 16 weeks after urethane. Tumors from 
IKKβΔmye mice contained significantly fewer blood vessels than those from WT mice 
(Figure 22B-C). Protein expression of vascular endothelial growth factor (VEGF), an 
NF-κB-regulated mediator of angiogenesis (213–215), was also reduced in the lungs of 
IKKβΔmye mice (Figure 22D). Taken together, these data suggest that inhibition of NF-κB 
signaling in myeloid cells limits tumor size by reducing angiogenesis.   
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Figure 22: IKKβΔmye mice have smaller lung tumors due to decreased angiogenesis. 
A) Diameters of surface lung tumors from WT and IKKβΔmye mice at 16 weeks after urethane 
injection (n=16-22 mice per group). B) Representative photomicrographs of lung sections 
from tumor-bearing WT and IKKβΔmye mice immunostained with antibodies against CD34. C) 
Blood vessel density in lung tumors from WT and IKKβΔmye mice was calculated as the 
number of CD34+ endothelial cells per square millimeter of tumor area (n=5-7 mice per 
group). D) Concentration of VEGF protein in the BAL of WT and IKKβΔmye mice harvested at 
16 weeks after urethane injection (n=7-8 mice per group). *p<0.05 by Student’s t-test 
compared to WT.  
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Previous studies have demonstrated roles for both macrophages and neutrophils 
in tumor angiogenesis. The presence of M2-like TAMs has been associated with 
increased tumor angiogenesis and poor patient prognosis in lung and other cancers 
(216–218). These TAMs support multiple steps required for angiogenesis, including 
degradation of the extracellular matrix as well as the migration and proliferation of 
endothelial cells (219). Our group has shown that depletion of macrophages during later 
stages of lung tumorigenesis suppresses tumor angiogenesis and decreases VEGF 
expression in the lung, identifying macrophages as a critical cell population for 
angiogenesis in lung tumor progression (186). Together with the current study, which 
shows a similar reduction in tumor vascularity and VEGF expression, these findings 
suggest that NF-κB signaling in macrophages and/or other myeloid cells supports the 
production of pro-angiogenic factors, as has been previously described for VEGF, 
MMP9, IL-1, TNFα, and FGF2 (215, 220–222). TANs have also been shown to play 
roles in tumor angiogenesis through MMP- and NE-mediated extracellular matrix 
degradation in models of hepatocellular carcinoma, chronic colitis-associated cancer, 
and pancreatic cancer (223–225). However, the role of TANs in lung tumor angiogenesis 
has not been determined. Studies comparing production of specific pro-angiogenic 
mediators from both WT and NF-κB-deficient TAMs and TANs may uncover different 
NF-κB-regulated mechanisms of tumor angiogenesis that can be targeted for cancer 
treatment. 
 
 
Role of the inflammasome in lung tumorigenesis 
Inflammasomes were first described in 2002 and have since become targets of 
interest for inflammatory conditions such as cryopyrin (NLRP3)-associated periodic 
syndrome, gout, diabetes, and, more recently, cancer (226, 227). Inflammasomes are a 
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group of molecular complexes comprised of a sensor/scaffolding protein (NLR), adaptor 
protein (ASC), and pro-caspase-1, which converts pro-IL-1β and pro-IL-18 to their 
processed, bioactive forms in response to various stimuli (228). Under non-cancerous 
conditions, activation of the inflammasome initiates an inflammatory cascade which 
results in immune cell recruitment for pathogen clearance. However, under cancerous 
conditions, inflammasomes can become constitutively active and contribute to 
metastasis, angiogenesis, and proliferation through IL-1β-mediated mechanisms (229). 
To determine the role of inflammasomes in lung cancer, we investigated tumor 
formation in response to the lung carcinogen urethane in mice deficient in caspase-1 
(Casp1 KO), the conserved enzymatic subunit of inflammasomes. Since Casp1 KO mice 
were on the tumor-resistant C57BL/6 background, we utilized a multi-dose urethane 
model (1 g/kg weekly for 4 weeks) (84) to induce tumorigenesis in these mice. We 
observed a significant decrease in lung tumor incidence and multiplicity in Casp1 KO 
mice compared to WT mice (Figure 23A-B), indicating a role for caspase-1 (and likely 
inflammasome signaling) in lung carcinogenesis. 
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Figure 23: Deletion of caspase-1 reduces reduces lung tumor incidence and number.  
Complete caspase-1 knockout mice (Casp1 KO) and WT control mice on the C57BL/6 
background were injected once weekly with urethane (1g/kg) for a total of 4 weeks. Mice were 
then maintained until harvest at week 16 after the first injection of urethane. A) Lung tumor 
incidence and (B) lung tumor number in Casp1 KO mice at 16 weeks after the first urethane 
injection (n=4-5 mice per group; *p<0.05 by Student’s t-test compared to WT). 
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The role of inflammasome components and products in lung tumorigenesis has 
not been comprehensively studied. Since caspase-1 processes and activates the 
inflammasome products IL-1β and IL-18, both of which can promote tumorigenesis (230, 
231), tumor studies almost always investigate caspase-1 for its role in inflammasome 
signaling. Thus, caspase-1 may mediate lung tumorigenesis through IL-1-mediated 
inflammatory mechanisms in immune cells. On the other hand, caspase-1 may also 
regulate survival/apoptosis of tumor cells, as has been described for colon cancer cells 
stimulated with IFNγ (232). A future direction of this work is to determine how caspase-1 
promotes lung carcinogenesis and to identify other critical components of the 
inflammasome complex that are necessary for increased tumor formation. Two 
potentially important inflammasome scaffolding proteins in lung cancer may be AIM2 and 
NLRP3, which were recently found to be overexpressed in both lung cancer cell lines 
and lung cancer tissues from stage 1 lung cancer patients. NLRP3 was the most highly 
expressed scaffold protein in high-grade adenocarcinomas (228). Mutations in NLRP3 
are present in 16% of lung adenocarcinomas, and these NLRP3-mutant lung tumors are 
enriched for NF-κB activity, suggesting that NLRP3 mutations as gain-of-function 
mutations that could promote cancer cell survival and/or mediate cancer-related 
inflammation (233). Very little is known about the role of AIM2 in lung cancer, but it may 
play a role in mediating immunosuppression in plasmacytoid dendritic cells (234). 
Another inflammasome component is the ASC adaptor protein, which is 
hypermethylated during late stages of lung cancer (235), indicating a potential role for 
inflammasome signaling in lung tumor progression and metastasis. ASC is thought to 
mediate tumor suppression under normal conditions by binding to IKKs and preventing 
inflammatory NF-κB signaling. However, under cancerous conditions, ASC binds to 
other subunits of the inflammasome complex, releasing IKK and allowing NF-κB 
activation. Low levels of ASC in advanced stage cancers are thought to be sequestered 
75 
 
into active inflammasome complexes so that unrestrained inflammatory signaling may 
occur (236). Because the field of inflammasome signaling is so new, there is much to be 
gained from investigating its potential role in facilitating lung tumorigenesis in order to 
identify additional targets for lung cancer treatment.  
Role of cathepsin G in lung carcinogenesis 
 
Our study shows that cathepsin G plays a role in lung tumorigenesis by 
processing pro-IL-1β in the context of NF-κB inhibition. This suggests that targeting 
cathepsin G might be of interest to overcome resistance to NF-κB inhibitor therapy. Very 
little is known about cathepsin G in lung cancer, and future studies will be necessary to 
determine its role in lung tumorigenesis with and without NF-κB inhibition. In lung cancer 
patients, cathepsin G expression in tumor-infiltrating neutrophils has been correlated 
with increasing disease grade and stage (206). A mouse model of lung metastasis 
showed that genetic co-deletion of cathepsin G and neutrophil elastase reduced lung 
metastases from LLC lung adenocarcinoma and B16-BL6 melanoma cells by degrading 
the anti-tumorigenic factor thrombospondin-1 (Tsp-1), suggesting that cathepsin G may 
play a role in lung metastasis (237). These two studies represent the only information 
currently available about cathepsin G in lung cancer. However, based on the literature, 
cathepsin G may also promote tumorigenesis through release/processing of chemotactic 
factors for inflammatory cell recruitment (238–240), angiogenesis via induction of TGFβ-
mediated VEGF and CCL2 or via induction of endothelial-derived growth factors (241, 
242), tumor cell invasion via activation of MMP2 (243), and formation of tumor cell 
aggregates, which are multicellular collections of tumor cells that can disseminate from 
the primary tumor and extravasate into the bloodstream or lymphatic system (244, 245). 
Another avenue of study that should be investigated is the relationship between NF-κB 
and cathepsin G. There is no current evidence that NF-κB regulates cathepsin G 
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expression. However, cathepsin G has been shown to cleave NF-κB subunit p65 in 
promyelocytic cells in vitro. It remains to be determined if this activity is relevant in vivo.  
 
Conclusion 
 
 The work presented in this dissertation has broad implications for inflammatory 
signaling, lung cancer biology, and future therapeutics. Our studies have demonstrated 
that the role of NF-κB signaling in disease is variable depending on cell type and 
preexisting environmental conditions. In lung cancer, NF-κB is activated in most tumors 
and supports epithelial cell survival and growth (83, 84, 86–88), yet inhibitors of the NF-
κB signaling pathway have little to no tumor effect in patients (101, 102). Our data 
suggest that the lack of response to NF-κB inhibitors is due to previously unrecognized 
pro-tumorigenic signaling in myeloid cells when NF-κB is suppressed. In other words, 
pro-tumor responses from NF-κB inhibition in myeloid cells counterbalance anti-tumor 
responses from NF-κB inhibition in epithelial cells such that the net effect of inhibitor 
therapy is negligible. Interestingly, the utility of a therapy appears to be related to its 
effect on inflammation, as reduction in inflammation leads to reduced tumors and vice 
versa in several different cancer models (78, 83, 84, 110, 176). In order to tip the 
balance toward an anti-tumor response to NF-κB inhibitor therapy, we identified and 
targeted the pro-tumorigenic mechanism of NF-κB-deficient myeloid cells during lung 
tumorigenesis. We found that neutrophils, a myeloid subpopulation, supported lung 
tumorigenesis by dysregulating processing of IL-1β through a novel cathepsin G-
regulated mechanism. Processed and activated IL-1β provided survival signals to 
epithelial cells. Using a novel combination therapy with bortezomib and IL-1ra, we were 
able to reduce lung tumor formation and growth. Since both bortezomib and IL-1ra are 
clinically available, these results provide strong support for investigation of this 
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combination therapy in lung cancer patients. The successful response to bortezomib and 
IL-1ra therapy in preclinical models emphasizes both the potential of and the need to 
explore additional combinations of targeted therapies in cancer treatment. Our approach 
to counteract mediators of resistance can be extended to other targeted therapies, such 
as angiogenesis and checkpoint inhibitors and may prolong patient response and 
improve survival.  
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